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ABSTRACT 
MUSCLE PLASTICITY AND INTRAMUSCULAR SIGNALING IN THE INSULIN- 
RESISTANT OBESE ZUCKER RAT 
By Anjaiah Katta 
 The ability to increase skeletal muscle mass may have important implications for the 
treatment of insulin resistance (IR) and diabetes [1-3]. Recent data suggest that IR muscle may 
adapt differently than normal muscle; however, molecular mechanism(s) responsible for this 
finding are not well understood [4]. Herein, we investigate the molecular mechanisms underlying 
the skeletal muscle remodeling in the IR Obese Zucker (OZ) rat. 
 The OZ rat is characterized by skeletal muscle
 
insulin resistance, hyperglycemia, and 
hyperlipidemia. Compared to LZ rats, our data demonstrate that soleus muscle hypertrophy was 
significantly attenuated in the OZ rats after 3-weeks of muscle overload and that these findings 
appear to be accompanied by significant impairments in the ability of the soleus to undergo 
phosphorylation of mammalian target of rapamycin (mTOR), 70 kDa ribosomal protein S6 
kinase (p70S6k), ribosomal protein S6 (rpS6) and protein kinase B (Akt).  
 Recent in vitro and in vivo studies have suggested a role for AMP-activated protein 
kinase (AMPK) and dsRNA-dependent protein kinase (PKR) in skeletal muscle adaptation and 
their interactions with mTOR related signaling [5, 6]. Our data suggest that IR attenuates 
overload-induced skeletal muscle hypertrophy through the activation of AMPK and PKR, which 
appears to be associated with an inhibition of mTOR and eIF2α phosphorylation. This finding is 
consistent with the possible depression of protein synthesis. Other data demonstrate that IR 
resistance is associated with the PKR-mediated activation of p38 MAP kinase, which would be 
predicted to lead to increased protein degradation. Further, we demonstrated that the regulation 
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of heat shock proteins (HSPs) and the mitogen-activated protein kinases (MAPKs) are altered 
during hypertrophy in OZ rat, which suggest that these molecules may play a role in explaining 
why IR may be associated with alterations in muscle plasticity. 
 In addition to traditional biochemical signaling cascades, recent data have strongly 
suggested that muscle-specific miRNAs may participate in the regulation of load-induced 
skeletal muscle remodeling [7]. To this end, we demonstrate for the first time that miR-1 and 
miR133 expression levels are lower in IR muscle. Further, we also observed that overload 
decreased mir-1 expression in the LZ muscle to a greater extent to that measured in the OZ 
muscle. Combined, these results are the first to report evidence that overload-induced skeletal 
muscle remodeling in IR OZ rat is associated with multiple level decrements including changes 
in mTOR signaling, hyperphosphorylation of AMPK and PKR and altered regulation of muscle-
specific miRNAs. 
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CHAPTER 1 
INTRODUCTION 
The incidence of diabetes is growing at epidemic proportions and is rapidly becoming a 
global health problem. According to the World Health Organization, the number of diabetics 
throughout the world was 171 million in the year 2000 and is estimated to be 336 million by 
2030. India is the diabetic capital of the world with the largest numbers of people with diabetes 
(40.9 million), followed by China (39.8 million), the United States (19.2 million), Russia (9.6 
million) and Germany (7.4 million) (International Diabetes Federation, 2007). Diabetes affects 
25.8 million people, or 8.3% of the United States population, including 7.0 million people who 
are unaware that they have diabetes (National Diabetic Fact Sheet, 2011). In 2010 it was 
estimated that 79 million American adults aged 20 years or older were prediabetic. Diabetes is 
the seventh leading cause of death in the United States and is associated with heart disease, 
stroke, peripheral vascular diseases, blindness, kidney failure and nervous system damage. The 
total cost of diabetes in the United States in 2007 was $218 billion (National diabetes statistics, 
2007). Given this setting, it is clear that the scientific community must continue to search for 
more effective methods to treat and prevent this disease.  
Skeletal muscle accounts for 80 to 90 percent of glucose disposal, and insulin sensitivity 
is thought to be a key factor in muscle glucose uptake [8]. A myriad of studies has shown that 
skeletal muscle insulin resistance is the key defect in maintaining glucose homeostasis and that 
skeletal muscle health is thought to play a central role in the pathogenesis of several components 
of the metabolic syndrome (MS) including obesity, diabetes, dyslipidemia, hypertension and 
atherosclerosis [9, 10]. Therefore, increasing skeletal muscle mass and improving function could 
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play an integral role in increasing glucose storage capacity and improving the regulation of 
glucose metabolism. 
 Previous studies demonstrated that different exercise modalities cause favorable 
metabolic adaptations in skeletal muscle, including significant increases in glucose transport and 
in the activities of enzymes involved in regulating glucose metabolism [11-14]. Recently we 
have demonstrated that diabetes affects contraction-induced signaling in skeletal muscle and 
have found differences in activation of MAPK signaling proteins between normal and diabetic 
rats immediately after and during the recovery phase of an acute bout of high-frequency 
electrical stimulation [15]. Further, we demonstrated that contraction induced activation of 
p70S6k signaling is altered in muscle of the insulin resistant obese Zucker rat [16].  
Various overload models have been developed to induce skeletal muscle growth and 
adaptations in animal models. They include stretch hypertrophy, compensatory hypertrophy, 
resistance training, alteration of hormonal levels and dietary supplementation. Mechanical 
overload in the form of synergistic ablation provides a chronic stimulus that initiates skeletal 
muscle adaptation by increasing the workload of selected muscles by ablation of a few or all 
synergistic muscles [17]. How skeletal muscle tissue "senses" and adapts to altered loading 
conditions with insulin resistance is not known. Furthermore, it is not known if the adaptive 
potential of insulin resistant muscle differs from that of non-diabetic controls. A greater 
understanding of how insulin resistant muscle responds to hypertrophic stimuli may help to 
unravel new treatment modalities for use in the diabetic population. 
Studies of exercise in vivo and stretch in vitro have established that increased loading of 
muscle cells induces growth [18, 19] and this growth is characterized by increases in protein 
synthesis [20, 21]. One critical signalling pathway controlling protein synthesis during 
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mechanically induced skeletal muscle growth involves the mammalian target of rapamycin 
(mTOR) [19, 22, 23].  mTOR protein lies downstream of Akt in the insulin signaling pathway, 
and is thought to integrate signals from metabolic, hormonal, nutritional and mechanical stimuli. 
The mTOR is also involved in regulating various physiological functions, including gene 
transcription, protein
 
metabolism, the cell cycle, and cytoskeleton organization [24, 25]. When 
active, mTOR promotes an increase in the efficiency and capacity for translation of mRNA to 
protein by increasing, either directly or indirectly, the activity of several proteins, including 70 
kDa ribosomal protein S6 kinase (S6k), ribosomal protein S6 (rpS6), eIF4E-binding protein 1 
(4E-BP1), and eukaryotic elongation factor 2 (eEF2) [26, 27]. S6k promotes the translation of 
various ribosomal proteins and elongation factors (including eEF2), presumably via 
phosphorylation of rpS6 [28], and also promotes a general increase in protein elongation by an 
indirect activation of eEF2 [29]. On the other hand, mTOR phosphorylation of 4E-BP1 promotes 
translation initiation of 5′-cap mRNAs, including most eukaryotic mRNAs [22, 23, 30], and 
enhances muscle protein synthesis [19, 31, 32]. 
Recent in vitro and in vivo studies have suggested that 5'
_
AMP-activated protein kinase 
(AMPK) and the dsRNA-dependent protein kinase (PKR) can play a role in the inhibition of 
protein synthesis [6, 26, 33, 34]. It has been shown that AMPK may inhibit protein synthesis 
through its ability to suppress mTOR activation [22, 34]. The factors controlling the activity of 
AMPK have not been fully elucidated, however it is thought that protein tumor suppressor LKB1 
kinase [35], calcium/calmodulin-activated protein kinase (CaMKII) [36] and transforming 
growth factor-β-activated kinase-1 (TAK1), a member of the mitogen-activated protein (MAP) 
kinase family,  may be involved [37]. PKR, when activated, phosphorylates eIF2α at Ser-51 [6], 
which in turn leads to translational inhibition and presumably a decrease in protein synthesis 
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[38]. In addition to its potential effect on protein synthesis, PKR may also have a hand in 
controlling the ubiquitin proteolytic pathway through the activation of p38 MAP kinase [39, 40]. 
Stress responsive proteins like heat shock proteins (HSP) and Mitogen-activated protein 
kinases (MAPKs) are thought to be involved in the regulation of protein synthesis. Previous 
studies demonstrated the induction of HSPs following high force eccentric contraction, aerobic 
exercise, and during the development of muscle hypertrophy [41-43]. Similarly, several studies 
demonstrated that the extracellular regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase 
(JNK) MAPK proteins are involved in the regulation of skeletal muscle hypertrophy following 
increased loading [44-47]. However, it is not clear whether the regulation of these molecules is 
altered with insulin-resistance. 
In addition to these signaling cascades, recent data have strongly suggested the role of 
muscle-specific miRNAs (miR-1, miR-133a and miR-206) in load-induced skeletal muscle 
remodeling [7, 48, 49]. MicroRNAs  are small endogenous ~ 22-nucleotide, non-coding RNAs 
and newly emerging class of trans-factors, which repress gene expression by inhibiting the 
translation of target mRNAs through interaction with the 3
’
- untranslated region (3’UTR) of 
target mRNAs [50, 51]. Among the muscle-specific miRNA’s, miR-1 and miR-133a are 
important for embryonic muscle growth [52] and  myoblast differentiation and proliferation by 
regulating the expression of SRF, MyoD and MEF2 [53]. miR-206 plays a role in myogenesis 
[54]. A recent study by McCarthy and Esser (2007) reported decreased expression of miR-1 and 
miR-133a following 7days of functional overload and suggested that this response acted to 
remove the repression of hypertrophic regulators [7]. How insulin resistance may affect the 
regulation of muscle-specific miRNAs during muscle hypertrophy is currently unclear. 
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SPECIFIC AIMS 
Diabetes is growing in epidemic proportions and is becoming a global health problem. 
The Obese Zucker (fa/fa) rat (OZ) presents a range of metabolic aberrations such as 
hyperinsulinemia, hyperglycemia, and hyperlipedemia along with central obesity [55]. These 
animals have point mutations in the leptin receptor gene, leading to the development of 
hyperphagia and obesity. It is thought that the OZR closely models the progression of metabolic 
syndrome seen in humans [56]. 
Previous studies have shown decreased muscle mass in OZ rat compared to LZ rat as 
reflected by muscle wet-weight, protein content, DNA, and RNA [57-61]. These alterations in 
muscle weights are very important because these changes are highly correlated with 
hyperglycemia, given that skeletal muscle accounts for 80 to 90 percent of glucose disposal. 
Recent work by Paturi et al., has shown that the capacity of the OZ  soleus muscle to undergo 
hypertrophy in response to increased loading is diminished compared to that observed in the LZ 
[4]. The molecular mechanism(s) responsible for the decreased adaptability of insulin resistant 
muscle is not well understood.  
Our long-term goal is to improve our understanding of how insulin resistance may affect 
the ability of skeletal muscle to adapt to changes in contractile activity. The central hypothesis of 
this study is that insulin resistance will be associated with alterations in the activation of  several 
signaling cascades in skeletal muscle in response to given hypertrophic stimuli and that these 
alterations in signaling pathway activation may be responsible for  altered skeletal muscle  
remodeling with insulin resistance. 
To test our central hypothesis and accomplish the objective of this study the following 
three specific aims are proposed:  
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SPECIFIC AIM I: To investigate whether insulin resistance affects the regulation of the mTOR 
signaling during muscle hypertrophy. (Paper I) 
 
SPECIFIC AIM II: To investigate whether insulin resistance affects the regulation of the 
AMPK and PKR during muscle hypertrophy. (Paper II) 
 
SPECIFIC AIM III: To investigate whether insulin resistance affects the regulation of the 
HSPs (HSP27, HSP60, HSP70 and HSP90), MAPKs (ERK1/2 and JNK) and muscle-specific 
miRNA’s (miR-1 and miR133a) during muscle hypertrophy. (Paper III)  
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CHAPTER II 
REVIEW OF THE LITERATURE 
A review of the pertinent literature concerning the present study will be presented in the 
following chapter. The following areas will be addressed: 1. Diabetes and skeletal muscle insulin 
resistance; 2. Different animal models of Type 2 Diabetes Mellitus (T2DM); 3. Different 
overload models of skeletal muscle hypertrophy; and 4. Molecular mechanisms of skeletal 
muscle adaptation to increased loading.  
2.1.1 Diabetes 
Diabetes mellitus (DM) is a disease characterized by elevated levels of blood glucose resulting 
from defects in insulin production, insulin action, or both. Insulin is a polypeptide hormone, 
secreted by the β-cells of the pancreas and regulates body glucose homeostasis. A deficiency or 
the inability of cells to respond to insulin leads to consistent hyperglycemia, which if allowed to 
proceed unchecked can lead to several complications. There are two major types of diabetes, 
type 1 (also called juvenile-onset or insulin-dependent) and type 2 (adult-onset or non-insulin-
dependent). Type 1 diabetes mellitus (T1DM) accounts for about five to ten percent of total 
diabetic cases and is characterized by inability of the pancreas to secrete insulin because of 
autoimmune destruction of the pancreatic β-cells [62]. Type 2 diabetes mellitus (T2DM) is the 
most common form of diabetes, which accounts for ninety to ninety five percent of all diagnosed 
diabetic cases [63]. T2DM is characterized by insulin resistance and/or abnormal insulin 
secretion, either of which may predominate. T2DM is considered a global health problem as it 
afflicts 171 million people worldwide (International Diabetes Federation, 2007). This epidemic 
is associated with increased mortality and morbidity, in particular due to cardiovascular 
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complications, and results in a number of complications that diminish the quality of life [64]. A 
better understanding of the mechanism(s) leading to the development of T2DM is needed to 
improve therapeutic and preventive strategies. 
2.1.2 Skeletal muscle insulin resistance 
It is a well known that skeletal muscle is the principal site for whole body glucose 
disposal and that insulin sensitivity is a key factor in the regulation of muscle glucose uptake. In 
healthy conditions, insulin tightly regulates glucose homeostasis by stimulating glucose uptake in 
peripheral tissues [65]. Insulin is released from  β-cells of the pancreas in response to elevated 
levels of glucose, and its binding to insulin receptor leads to translocation of glucose transporters 
to the membrane and increased skeletal muscle uptake of glucose [65]. Insulin resistance (IR) 
refers to the decreased ability of insulin to stimulate glucose uptake in insulin sensitive tissues 
such as skeletal muscle and fat and to decrease glucose production in the liver. Skeletal muscle 
IR is the key defect in maintaining glucose homeostasis and is  thought to play a central role in 
the pathogenesis of several components of the metabolic syndrome (MS) including obesity, 
diabetes, dyslipidemia, hypertension and atherosclerosis [9, 10]. Chronic hyperglycemia, a 
hallmark feature of diabetes, is shown to associate with reactive oxygen species (ROS) 
production, lipid peroxidation, and decreased antioxidant defenses [66]. However, the 
mechanisms responsible for development of IR and IR-mediated alterations in the adaptation of 
skeletal muscle to different components of the MS are poorly defined. Because of the key role of 
skeletal muscle IR in the pathogenesis of several components of the MS, it has been postulated 
that interventions that could enhance skeletal muscle mass and function may act to improve 
insulin action in different insulin sensitive tissues. 
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 Different exercise modalities cause favorable metabolic adaptations in skeletal muscle 
and improve insulin action, including significant increases in glucose transport and activities of 
enzymes involved in glucose metabolism, by upregulating several proteins of insulin signaling 
[11-14]. The exact molecular mechanisms underlying the skeletal muscle remodeling with a 
given contractile stimulus are not yet understood. A review on the different molecular 
mechanisms of skeletal muscle adaptation to increased loading is presented in subsection 4 of 
chapter II. 
2.1.3 Skeletal muscle mass 
Skeletal muscle is the most abundant tissue in the human body. The maintenance of 
muscle mass is essential for overall health, functionality and quality of life. Skeletal muscle 
constitutes 55 percent of the body weight and is the primary tissue for glucose and lipid 
utilization. Attenuated muscle mass associated with obesity and T2DM could be particularly 
detrimental as blood glucose and lipid levels increase and the ability to utilize each is diminished 
[67]. The obese zucker rat (OZR) is characterized by significant reduction in muscle mass, even 
though its body weight is significantly higher compared to the LZ  rat phenotype [15, 57, 68]. 
Identification of molecular mechanism(s) that are associated with altered skeletal muscle 
adaptation with T2DM may lead to prevention of the development of complications that are 
associated with insulin resistance.  
2.1.4 Summary 
  Type 2 diabetes mellitus (T2DM) is considered as epidemic of the 21
st
 century. Skeletal 
muscle plays an important role in glucose homeostasis and skeletal muscle insulin resistance is a 
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major metabolic defect leading to T2DM. A better understanding of the mechanism(s) leading to 
the development of T2DM is necessary to prevent the complications associated with this disease.  
2.2 Animal models of Type 2 Diabetes Mellitus (T2DM) 
Animal models of T2DM are excellent tools to study the pathophysiology of human disease. 
Knowledge about the manifestation of T2DM and the possible causes has expanded due to the 
utilization of animal models. Many of these animal models are developed using selective 
breeding, which typically produces specific genetic mutations in order to obtain a desired 
phenotype. Other methods for developing diabetic rodent models include gene targeting and 
transgenic techniques [69]. The following are some of the animal models that are commonly 
used in the field of diabetic research. 
2.2.1 ob/ob mouse 
The ob/ob mouse was developed by mutation of chromosome 6 in the C57BL/6J strain 
[70]. The mutation is in the ob gene, which encodes for leptin protein and causes these mice to 
become hyperphagic and develop obesity. Ob/ob mice exhibit a diabetes like syndrome that is 
characterized by mild hyperglycemia, mildly impaired glucose tolerance, severe 
hyperinsulinemia, insulin resistance, and impaired wound healing [71].  
2.2.2 db/db mouse 
 The db/db mouse was developed by an  autosomal  recessive mutation on chromosome 4 
in the C57BL/KSJ strain [72]. The mutation is in the db gene, which encodes for leptin receptors. 
These mice are spontaneously hyperphagic and develop insulin resistance within the first month. 
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In later stages, these animals exhibit nephropathy, neuropathy, vasculopathy and myocardial 
disease in a manner similar to that seen in human T2DM [72]. 
2.2.3 KK mouse 
  The KK mouse which was developed by inbreeding Japanese mice, displays moderate 
obesity, polyphagia, polyuria, persistent glucosuria and moderate hyperglycemia with 
hyperlipidemia [73]. These animals, in their later stages, develop renal lesions similar to human 
nephropathy including glomerular basement membrane thickening and proteinuria [74].  
2.2.4 Nagoya-Shibata-Yasuda (NSY) mouse 
The NSY mouse was developed by selective inbreeding and develops diabetes 
spontaneously in an age-dependent manner. These are non-obese and characterized by mild 
insulin resistance and marked impairment in insulin secretion. This model is particularly useful 
when considering age-related phenotypes (e.g., decline in β-cell function) [69]. 
2.2.5 New Zealand Obese (NZO) mouse 
 The NZO mouse is a polygenic model of diabetes and obesity developed by selective 
inbreeding and exhibits hyperphagia, obesity, mild hyperglycemia, hyperinsulinaemia, impaired 
glucose tolerance and insulin resistance. There is marked hyperplasia and hypertrophy with islets 
composed of up to 90 per cent of beta cells [72]. 
2.2.6 Goto Kakizaki (GK) rat 
 The GK rat is a non-obese model of T2DM. It was developed by selective breeding of 
the Wistar rats and is characterized by non-obesity with relatively stable hyperglycemia, 
hyperinsulinemia and insulin resistance [75]. The primary defect in these rats is in the beta cells 
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with “starfish-shaped” abnormalities. Later stage complications include nephropathy with 
thickened glomerular basement membrane, osteopathy, structural changes in peripheral nerves 
and altered retinal endothelial retinopathy [69, 76]. The GK rat serves as an ideal model to study 
diabetes without the contribution of dyslipidemia or obesity. 
2.2.7 Zucker fatty rat 
 The Zucker (fa/fa) fatty or obese rat was developed by a simple autosomal recessive 
mutation on chromosome 5, which encodes the leptin receptor. The impaired leptin receptor 
mediated counter regulation leads to increased levels of circulatory leptin in these rats [77]. The 
classical orexigenic peptides such as neuropeptide Y, galanin, orexins and melanin-concentrating 
hormone are upregulated in OZ rats [78-80]. These animals show mild hyperglycemia, insulin 
resistance, mild glucose intolerance, hyperlipidemia, hyperinsulinemia, and moderate 
hypertension while they also mimic the early stage of human T2DM. The OZ rats present 
abnormalities similar to those seen in human metabolic syndrome and are a widely used model 
of insulin resistance [56]. 
2.2.8 Zucker diabetic fatty rat 
 This model is a substrain of Zucker fatty rat selectively inbred for hyperglycemia. In 
contrast to fa/fa rats, these rats have limited ability to show hyperinsulinemic responses to 
compensate for peripheral insulin resistance [71]. These animals exhibit impaired insulin 
response to hyperglycemia by the β-cells of pancreas, although the response remains intact to 
nonglucose secretogogues like arginine in a manner similar to human T2DM. 
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2.2.9 Otsuka Long Evans Tokushima Fatty (OLETF) rats 
 The OLETF rats exhibit hyperglycemia, insulin resistance, hypertension, obesity and 
hypertriglyceridemia with marked triglyceride infiltration into pancreatic islets [70, 81]. These 
rats are also characterized by diminished expression of GLUT-4,which plays a key role in 
skeletal muscle glucose transport,and the distribution of GLUT-4 in these rats is characteristic of 
human T2DM [82, 83]. 
2.2.10 Psammomys obesus gerbil 
The Psammomys obesus (sand rat) gerbil is a normal inhabitant of the desert; when their 
native diet is substituted with laboratory diet for few weeks they develop insulin resistance with 
hyperinsulinemia [84, 85]. It has been shown that insulin resistance in these gerbils is associated 
with diminished insulin receptor action, increased serine phosphorylation of insulin receptor 
substrate (IRS) and increased in the activity of an enzyme of the protein kinase isoenzyme group, 
protein kinase C epsilon (PKCε) [86, 87].  
2.2.11 Obese rhesus monkey 
 When maintained on an ad libitum diet, the obese rhesus monkey develops obesity, 
hyperinsulinemia, and insulin resistance over time [88]. The deposition of amylin/amyloid in β-
cells in the later stages of diabetes is similar to human T2DM, where islet amyloid is commonly 
found in 90% of cases [89]. 
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2.2.12 Summary 
Various animal models have been developed to address the understanding of the 
pathology of T2DM. These animal models present with a diversified pathology and allow 
scientists to further explore the possible genetic, cellular, molecular, and environmental factors 
that contribute to this costly global epidemic. 
2.3 Overload models of skeletal muscle hypertrophy 
This section will summarize briefly various animal models of overload for skeletal 
muscle hypertrophy. These paradigms include stretch hypertrophy, compensatory hypertrophy, 
resistance training, alteration of hormonal levels and dietary supplementation. 
2.3.1 Stretch hypertrophy 
 It is a well known fact that muscle when lengthened undergoes hypertrophy, and that 
muscle maintained in a shortened position will atrophy. The functional and hypertrophic 
responses from different animal models of stretch like chicken and quail wing muscles [90-94] 
rabbits [95] and rats [96] are quite similar. The stretch-induced muscle adaptations include 
muscle hypertrophy, hyperplasia, increased muscle fiber length and contractile function in both 
fast and slow myosin-containing fibers [97, 98]. The hypertrophic response to this model is 
shown to be much greater than the functional overload model [99, 100]. The main advantages of 
this model include that it can be performed in a non-surgical manner and that it also induces 
hyperplasia, thus providing an opportunity to study mechanisms of new fiber formation. In 
contrast, some of the disadvantages of utilizing this model include the stimulus provided and 
magnitudes of adaptations are clearly not the same as progressive resistance training (PRT), and  
connective tissue content increases,whereas it is hardly evident with PRT [98]. 
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2.3.2 Compensatory hypertrophy 
When one of the synergistic muscles is removed or made inactive, the remaining muscles 
must compensate for the loss and undergo hypertrophy. Three different procedures for 
compensatory overload include tenotomy, synergist ablation and denervation.  
Tenotomy is the oldest method used to induce hypertrophy. It involves severing the 
tendon of synergist muscle. Goldberg et al., (1975) demonstrated  that tenotomy of the 
gastrocnemius for 5 days resulted in  a 40% increase in soleus muscle mass and a 20% increase 
in plantaris muscle mass [96]. This procedure produces a large initial hypertrophic response; 
however, most of it is due to edema due to surgery. Some of the main disadvantages of this 
procedure include tendon reattachment after a few days and lack of a recovery period from 
overload compared to normal hypertrophy from the resistance training model.  
The synergist denervation method for overload involves denervating the synergist 
muscles.  For example, denervation of branches of the tibial nerve that innervates gastrocnemius 
and soleus results in an increase in muscle mass of  the plantaris by 40% after 21 days [101]. The 
advantage of the synergist denervation model includes lesser bleeding during the surgical 
procedure, decreased inflammatory response post- surgery, and a faster recovery compared to the 
surgical ablation procedure. 
Synergistic ablation involves removal of the synergistic muscle completely, and large 
numbers of studies have utilized this model to study skeletal muscle hypertrophy. The 
hypertrophic response with this model was significant and persistent rather than transient [102, 
103]. Synergist ablation involves an immediate short-term inflammatory response and much 
slower long-term response in which the muscle undergoes functional and true hypertrophy. The 
main advantages of  the synergist ablation model for compensatory hypertrophy are utilizing the 
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contra lateral non-surgical limb as the control, a large and relatively rapid hypertrophic response, 
and freedom from complications of tendon reattachment as in the tenotomy method [98]. On the 
other hand, the disadvantages include post-surgical complications like inflammation and edema, 
and the lack of similarity with progressive resistance training as it lacks a recovery period from 
mechanical overload [98]. 
Various structural and functional adaptations of skeletal muscle hypertrophy by synergist 
ablation have been well defined [104-111]. Nonetheless, very little is known about adaptation in 
diabetic skeletal muscle with overload. Armstrong and Ianuzzo (1977) reported differences in the 
adaptation of skeletal muscle between normal and streptozotocin-induced diabetic rat muscles. 
This study revealed a 53% greater plantaris muscle weight in normal compared to diabetic rats, 
and  after 60 days of ablation surgery, the muscles were hypertrophied and increased by 79% and 
61% in normal and diabetic muscle compared to their respective contralateral control muscles. 
Another interesting finding revealed the slow-twitch fibers in diabetic rats were capable of 
responding to the overloaded condition but that the fast-twitch fibers had a reduced capacity to 
undergo compensatory growth [112]. These findings indicate that differences may exist in the 
response and adaptation to hypertrophy between the diabetic and normal muscle. The underlying 
mechanism(s) to explain the differences in these adaptations at cellular and molecular level 
remain to be elucidated. 
2.3.3 Resistance training 
  Several animal models mimicking progressive resistance training (PRT) have been used 
to study the effects of resistance training on muscle adaptation. High frequency electric 
stimulation model was used to induce eccentric contraction of rat soleus [18]. For example, using 
a modification of Booth’s original model, Wong and colleagues [113] trained rat soleus 
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eccentrically as a countermeasure for non-weight bearing muscle atrophy. Another model used 
for weight training in animals is the ladder climbing exercise. Animals are been trained to climb 
vertically with weight attached to their tail [114-117]. Such studies have demonstrated a 5 - 26% 
increase in relative muscle mass. Results of these studies vary because of differences in training 
protocol, species and muscles studied. The main advantage of the resistance training model is 
that most of the characteristics of this model like magnitude, time course of muscle hypertrophy, 
and strength gains are similar to human PRT. On the other hand, some of the disadvantages 
include difficulty in exercising animals voluntarily, training results in bilateral hypertrophy so 
that internal control is not possible, and slower adaptations when compared to other models of 
hypertrophy. 
2.3.4 Hormone induced hypertrophy 
  Growth factors are thought to be involved in muscle hypertrophy [118]. Important growth 
factors for skeletal muscle hypertrophy include insulin-like growth factor (IGF), fibroblast 
growth factor (FGF), and hepatocyte growth factor (HGF). These growth factors work in 
conjunction with each other to cause skeletal muscle hypertrophy. Song et al., (2005) reported 
that overexpression of IGF-I in mice skeletal muscle results in hypertrophy, which is likely 
mediated  by the mTOR/p70S6K pathway, potentially via an Akt-independent signaling pathway 
[119]. Growth hormone (GH) is a peptide hormone that stimulates IGF in skeletal muscle, 
promoting satellite cell activation, proliferation and differentiation [120]. For example, GH 
administration to a hypophysectomized animals increased muscle mass, total protein, RNA 
content, ribosome content and enzymes related to protein synthesis compared to non-GH 
treatment group [121]. In addition to growth factors and GH, testosterone has anabolic effects 
and induces muscle hypertrophy by increasing the protein synthesis [122]. Further, Brown et al., 
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(2009) showed that testosterone-induced muscle hypertrophy is associated with activation of 
notch signaling and the inactivation of JNK together with the activation of p38 MAPK [123]. 
2.3.5 Diet induced hypertrophy 
Several studies have shown that creatine supplementation in conjunction with resistance 
training augments gains in muscle strength and size [124-127]. Recent work by Hulmi et al., 
(2010) reported that augmented whey protein intake along with resistance exercise led to 
significant rises in muscle protein synthesis and cross sectional areas [128, 129]. In addition, 
ingestion of essential amino acid (EAA) has been shown to have positive effects on muscle 
hypertrophy and architecture [130, 131]. Several other supplements such as clenbuterol, beta-
hydroxy-betamethlbutyrate (HMB) and  branched-chain amino acids (BCAA) have been utilized 
to induce skeletal muscle hypertrophy [132]. 
2.3.6 Summary 
Different animal models of skeletal muscle hypertrophy have been employed to 
understand the different aspects of skeletal muscle adaptation. The functional and hypertrophic 
responses of most of these models are analogous to PRT in humans. Rapid and large degrees of 
persistent hypertrophy are induced by synergist ablation and provide an opportunity to 
investigate the mechanisms of muscle remodeling.  
2.4 Molecular mechanisms in skeletal muscle adaptation to increased loading 
Numerous possible signaling pathways involved in muscle adaptation have emerged as a 
consequence of the rapid progress in the understanding of the molecular mechanisms underlying 
skeletal muscle adaptation to increased load. This section is focused on reviewing some of the 
key molecular mechanisms in skeletal muscle adaptation including mammalian target of 
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rapamycin (mTOR) signaling, AMP-activated protein kinase (AMPK) signaling, dsRNA-
dependent protein kinase (PKR) signaling, stress protein signaling and muscle specific miRNA 
regulation. 
2.4.1 mTOR Signaling 
The mammalian target of rapamycin (mTOR) receives and integrates signals exerted by 
hormonal factors, nutrients, and energy status, and plays critical roles in a wide variety of 
physiological functions, including gene transcription, growth, cell cycle, cytoskeletal 
organization, and the regulation of protein synthesis at both transcriptional and translational 
levels [24, 25]. mTOR is a Ser/Thr kinase that belonging to the phosphoinositol-3-kinase (PI3K) 
related family of kinases, with a molecular weight of 289 kDa [133]. It contains 2549 amino 
acids and has several structurally conserved domains. The C terminus consists of a FKBP-
rapamycin binding (FRB) domain and a catalytic kinase domain, and the N terminus consists of 
two clusters of Huntington, elongation factor 3, the A subunit of protein phosphatase 2A, and 
TOR1 (HEAT) repeats [134]. 
2.4.1.1 mTOR complex and function 
mTOR exists in two complexes, mTORC1 and mTORC2. mTORC1 consists of 
mammalian lethal with SEC13 protein 8 (mLST8, also known as G protein beta subunit-like 
protein (GβL)), raptor and mTOR [135].  
 
\ 
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Figure 1: The mTOR complexes.  In mTORC1, the mTOR catalytic subunit associates with 
raptor and mLST8 (also known as GβL). mTORC2 in contrast, contains instead of raptor a 
protein called rictor, but also other subunits such as mLST8 and mSin1. 
 
This complex is rapamycin sensitive and mainly responsible for regulation of the size of the cell. 
mTORC2 consists of mLST8, rictor and mTOR. The mTORC2 is rapamycin insensitive plays a 
key role in actin cytoskeleton organization and regulation of  the shape of the cell [135]. 
2.4.1.2 Downstream targets of mTOR 
  The two important downstream targets of mTOR are p70 S-6 kinase (p70S6K) and 
eukaryotic initiation factor 4E- binding protein 1 (eIF4E-BP1), which are important factors in the 
protein synthetic pathway [133].  p70S6K and eIF4E-BP1 coordinate the translation of proteins, 
the regulation of eukaryotic initiation factors and ribosomes [136].  p70S6K is a Ser/Thr protein 
kinase that is required for cell growth and G1 cell progression is thought to be an important 
signaling intermediate that leads to the activation of protein synthesis and muscle hypertrophy 
[137]. The primary structure of p70s6k consists of four functional domains or modules and the 
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activation of p70s6k occurs in a hierarchal fashion through the sequential phosphorylation of 
each module [137].  Activation of  this kinase causes activation or phosphorylation of the S6 
protein of the 40S ribosomal subunit [138]. The activation of both kinase and its substrate 
accelerates the translation of specific mRNAs containing a terminal oligopolypyrimidine (TOP) 
track at the 5’ end that encode mainly ribosomal proteins and elongation factors. This is 
important as the regulation of TOP containing proteins has been postulated to be a rate limiting 
step in protein synthesis [139]. Rapamycin (mTOR inhibitor) treatment inhibits p70S6K 
activation both in vitro and in vivo and is associated with inhibition of 5’ TOP mRNA translation 
[22, 140]. Baar and Esser (1999) reported that p70S6K activation (phosphorylation) correlates 
highly correlated with muscle hypertrophy following resistance exercise [30]. 
 
Figure 2:  mTOR signaling: different downstream effectors 
 
 Translation repressor protein 4E-BP1 (also known as PHAS-1) is another important downstream 
effector of mTOR.  4E-BP1 normally exists in a dephosphorylated form, bind to and inhibit the 
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eukaryotic initiation factor 4E (eIF4E), and inhibits cap-dependent translation. When 4E-BP1 is 
phosphorylated by mTOR and other protein kinases it is dissociated from eIF4E resulting in 
increased formation of  the eIF4F complex and increased translational initiation [141]. mTOR 
also regulates translational elongation along with translational intiation as discussed above by 
regulating the elongation factor, eEF2 [142]. The mTOR dependent regulation of eEF2 kinase 
involves its phosphorylation at several sites, including Ser366, Ser78 and Ser359 [142].  
2.4.1.3 Control of mTOR by PI3K/Akt signaling 
mTOR signaling is regulated by growth factors and hormones, which is believed to be 
mediated through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. The interaction of 
insulin and growth factors with their receptors leads to the activation of phosphoinositide 3-
kinase (PI3K). PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate, which results in the 
production of phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3 ], that in turn leads to the 
activation of Akt or protein kinase B(PKB) [143]. Akt is a Ser/Thr kinase which lies upstream of 
mTOR signaling where it participates in regulation  the expression of genes involved in protein 
synthesis and atrophy [144]. Complete activation of Akt requires phosphorylation of both Thr 
308 and Ser 473 residues. Akt has been shown to be implicated in muscle hypertrophy [22], and 
overexpression of AKT in rat muscle by transfection [145] or genetic manipulation [146] 
increases muscle fiber diameter. Akt can influence the activity of mTOR through its ability to 
phosphorylate TSC2 (tuberous sclerosis
 
complex 2) at Thr1462 [147, 148]. TSC2 acts as a 
GTPase-activator protein (GAP) for the small G-protein Rheb (Ras-homolog enriched in brain), 
and phosphorylation of TSC2 inhibits its GAP activity, allowing Rheb to accumulate in its active 
GTP-bound form where it stimulates the kinase activity of mTOR [149, 150].  
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Figure 3: Scheme of different possible upstream regulators of mTOR signaling, based on the 
available knowledge in the literature. 
 
In addition to positive regulators, these processes are also influenced by negative modulators. 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a phosphatase and central 
negative regulator of the PI3K/AKT/mTOR signaling cascade that transduces signals regulating 
growth, survival and proliferation [151]. PTEN is thought to function by removing the phosphate 
from the D3 position of phosphatidylinositol 3,4,5-triphosphate (PIP3), thereby directly 
antagonizing the action of the phosphatidylinositol 3-kinases (PI3K) [152]. 
2.4.1.4 Regulation of Hypertrophy by the mTOR signaling 
A large part of tissue or organ hypertrophy is mediated through mTOR signaling. 
Different positive regulators of cell growth like growth hormone, insulin, IGF-I and nutrient 
availability are shown to stimulate hypertrophic muscle protein synthesis via the mTOR 
signaling pathway [153-156]. Negative hormonal factors such as glucocorticoids, pro-
inflammatory cytokines, and the TGF-β superfamily member myostatin, are known to inhibit 
hypertrophic muscle protein synthesis via the mTOR signaling pathways [157, 158]. Skeletal 
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muscle hypertrophy is an adaptation to muscle overload and is the result of an increase in protein 
synthesis. An increase in protein synthesis allows new contractile filaments to be added to the 
muscle fiber, thus increasing its size. It is well accepted that increases in protein synthesis 
precede skeletal muscle growth and that this process is regulated, at least in part, by mTOR and 
its signaling intermediates [22, 23]. It is currently unclear how mTOR signaling may be 
regulated in insulin resistant skeletal muscle. 
2.4.2 AMPK Signaling 
AMP-activated protein kinase (AMPK) is a serine/threonine kinase and is considered a 
master regulator of cellular energy metabolism due to its role in the regulation of glucose, lipid, 
and protein metabolism. AMPK is responsible for down regulating protein synthesis, glycogen 
synthesis and cholesterogenesis [106, 159, 160]. AMPK is activated when there is decreased 
energy status of the cell that elevates the AMP/ATP ratio. This can occur through either 
increased ATP consumption or decreased ATP production. Several pharmacological agents like 
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), metformin, and the peroxisome 
proliferator-activated receptor gamma PPAR-γ agonist rosiglitazone appear to activate AMPK 
[161-163]. Once activated, AMPK switches on several catabolic pathways such as glycolysis and 
fatty acid oxidation and switches off several ATP- consuming pathways such as lipogenesis and 
cholesterol biosynthesis [5]. 
2.4.2.1 AMPK structure and function  
AMPK is a heterotrimeric enzyme complex consisting of a catalytic subunit (α) and two 
regulatory subunits (β, γ). Each catalytic subunit is encoded by different genes. There are two 
isoforms of both the α- (α1 and α2) and the β-subunits (β1 and β2), and three isoforms of the γ-
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subunits (γ1, γ2, and γ3). The α subunit (63 kDa) contains the kinase domain at the N terminus, 
plus a C-terminal regulatory domain containing an autoinhibitory region that inhibits the kinase 
in the absence of AMP [164]. The α1 isoform is predominantly found in cardiac and skeletal 
muscle while the α2 isoform is predominant in pancreatic islet β-cells [165]. The β subunits act 
as “scaffold” that binds the α and γ subunit via conserved KIS and ASC domains. The β2 subunit 
is predominantly expressed in skeletal muscle and β1 predominates in the liver. The γ3 isoform 
expression is predominant in glycolytic skeletal muscle and γ1 and γ2 show broad tissue 
distributions [166]. The γ subunit contains a core cystathionine β-synthase (CBS) domain that 
appears to function in the binding of AMP [167]. 
2.4.2.2 Biochemical regulation of AMPK  
The regulation of AMPK is complex and involves an AMP-dependent conformational 
change, phosphorylation by upstream kinases, and decreased dephosphorylation by protein 
phosphatases. Increases in AMP levels enhance the binding of AMP to the γ subunit, leading to 
conformational changes in the AMPK molecule and inhibit the dephosphorylation of AMPK by 
protein phosphatases [168]. Different possible upstream kinases have been identified for AMPK, 
including the protein tumor suppressor LKB1 kinase LKB1 complex [35, 169, 170], the 
calcium/calmodulin-activated protein kinase (CaMKII) [36, 171] and transforming growth 
factor-β-activated kinase-1 (TAK1), a member of the mitogen-activated protein (MAP) kinase 
family [37, 172]. LKB1 is a tumor suppressor that phosphorylates AMPK at site Thr172 of the α-
subunit [170]. LKB1 knockout mice were reported to have diminished AMPK activation and 
suppressed glucose transport caused by both electrically stimulated contraction and treatment 
with AICAR and phenformin [35]. LKB1 can function as an AMPK kinase only when AMP 
enables the kinase access to the activating phosphorylation site of AMPK [173]. CaMKII 
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regulates AMPK in a Ca2+/ calmodulin-dependent, AMP-independent manner. The activity of 
CaMKII is Ca2
+
dependent [174]. Lack of TAK1 in cardiac muscle was shown to prevent the 
phosphorylation of AMPK (Thr172) induced by treatment with metformin [172]. 
2.4.2.3 Regulation of hypertrophy by the AMPK signaling 
Activation of skeletal muscle AMPK during conditions of energetic stress is thought to 
act as a negative regulator of protein synthesis and may therefore modulate skeletal muscle mass 
and hypertrophy [5, 26, 34]. This negative regulation of protein synthesis by AMPK activation 
has also been reported in cardiac muscle [175, 176]. The inhibition of protein synthesis by 
AMPK appears to occur through the down regulation of mTOR and mTOR-dependent signaling 
proteins [5]. This down regulation of mTOR signaling by AMPK is likely due to direct  
phosphorylation of  tuberous sclerosis complex 2 (TSC2) at Thr1227 and Ser1345, which 
subsequently inactivates the G-protein Rheb thereby blocking activation of mTOR [177, 178]. 
This notion is further extended by a recent study showing that AMPK deletion is associated with 
increase in p70S6K Thr389 and rpS6 Ser-235/236 phosphorylation, and an enhanced protein 
synthesis rate [179]. AMPK activation has been shown to have a negative correlation with 
overload induced hypertrophy in plantaris muscles of aged rats [180]. The regulation of AMPK 
signaling during muscle hypertrophy in insulin resistant skeletal muscle has, to our knowledge, 
not been studied. 
2.4.3 PKR Signaling   
2.4.3.1 PKR structure and function   
The dsRNA-dependent protein kinase (PKR) was first described as p68 kinase in human 
cells and as p65 kinase in murine cells on the basis of electrophoretic mobility in SDS [181]. 
 27 
 
PKR consists of a regulatory domain at the N-terminus, which contains the binding sites for 
dsRNA, and a protein kinase binding domain at the C-terminus [182, 183]. It is thought that the 
binding of dsRNA to PKR exposes the ATP binding domain and results in autophosphorylation 
of PKR on multiple serine and threonine residues [181]. Once activated, PKR phosphorylates 
exogenous substrates. The best characterized substrate of PKR is the small subunit of the 
eukaryotic initiation factor 2 (eIF2α). PKR phosphorylates eIF2α at Ser-51, which functions to 
inhibit translational initiation [6].  
2.4.3.2 Regulation of muscle mass by PKR signaling  
  Several in vitro and in vivo studies in the last few years strongly suggest a role for 
dsRNA-dependent protein kinase (PKR) in both protein synthesis and degradation processes [6, 
33, 184, 185]. PKR regulates protein synthesis through  phosphorylating eIF2α at Ser-51, thereby 
inhibiting translational initiation [6]. In addition, recent studies have reported that 
hyperglycemia, TNF-α and Ang II induced protein degradation are associated with caspase-3/-8 
mediated activation of PKR [33, 186]. PKR is also thought to be involved in the regulation of 
protein degradation by its ability to influence the ubiquitin- proteasome pathway, most likely by 
mechanism involving the activation of p38 MAPK [40] and the transcription factor nuclear 
factor-κB (NF-κB) [39]. How insulin resistance may affect the regulation of PKR during muscle 
hypertrophy has, to our knowledge, not been investigated. 
2.4.4 Stress signaling  
 2.4.4.1 Heat shock protein (HSP) signaling and regulation of hypertrophy   
HSPs, also called stress proteins, are important components of the cellular protective 
response and fulfill diverse functions, including chaperoning unfolded proteins, inhibiting 
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apoptosis, and stabilizing the cytoskeleton [187-191]. They are subdivided into several classes 
according to their molecular weights. The most commonly abundant HSPs in muscle are small 
HSPs like HSP27 and large molecular weight proteins like HSP60, HSP70 and HSP90. These 
stress proteins provide protection in response to a wide variety of stressors such as hypoxia, free 
radical stress, energy deprivation, increased temperature and exercise [192-194].  
HSPs function as chaperones during protein synthesis by binding to the nascent 
polypeptide chains and preventing improper folding [191]. This chaperone function of HSPs 
make them good candidates for being involved in muscle hypertrophy, which includes adding 
new proteins to the existing muscle fibers. HSPs also appear to  modulate actin dynamics and 
assist in the preservation of muscle mass at the tissue level [195]. Shue and Kohtz (1994) 
reported that HSP90 activates the muscle specific transcription factor MyoD and functions to 
promote increases in muscle mass through the activation of specific genes and satellite cells  
[196].  
HSPs are thought to be regulated by phosphorylation at specific sites. For example, 
HSP27 is  regulated by phosphorylation at two sites in the rat (Ser-15 and Ser-85) and the mouse 
(Ser-15 and Ser-86) and at three sites in humans (Ser-15, Ser-78, and Ser-82) [197]. These 
phosphorylation events are thought to be mediated by mitogen-activated protein kinases 
(MAPKs) [197]. Several previous studies demonstrated the stress response with high force 
eccentric contraction, the aerobic exercise model (cycling and running), and compensatory and 
stretch-induced hypertrophy [41-43]. No studies to date have investigated the response of HSPs 
in insulin-resistant skeletal muscle to functional overload.  
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2.4.4.2 MAPKs signaling and regulation of hypertrophy   
Mitogen-activated protein kinases (MAPKs) are another class of stress responsive 
proteins, capable of regulating cellular processes such as protein synthesis, cellular proliferation, 
differentiation, and apoptosis [198-200]. The MAPK family of proteins are divided into four 
major subfamilies, including extracellular signal-regulated kinases (ERK), p38 MAPK, c-Jun 
NH2-terminal kinases (JNK), and extracellular signal-regulated kinase 5 [201]. The MAPK 
pathways consist of a cascade of kinase intermediates that phosphorylate and activate in specific 
order: MAPKKKK (Ras)  MAPKKK (Raf)  MAPKK (MEK) MAPK. 
  The MAPKs are activated by dual phosphorylation and then translocated to the nucleus, 
where they are capable of regulating such diverse process such as gene expression, glucose 
uptake, cell replication, protein synthesis and apoptosis [202, 203]. The ERK signaling cascade 
plays a primary role in cell proliferation or mitogenesis and has been shown to regulate cell 
development, differentiation and survival [204]. Pearson et al., (2001) reported that ERK1/2 
activation or phosphorylation at Thr202 and Tyr204 leads to activation of several transcriptional 
factors including cAMP response element binding protein (CREB), Elk, c-jun and c-fos, [205]. 
ERK may also play a role in modulating protein synthesis by regulating mTOR activity through 
inhibition of the TSC complex [206]. In T2DM, oxidative stress and inflammotry cytokines 
stimulate P38 and JNK MAPKs [66, 207]. JNK activation or phosphorylation is shown to 
modulate several transcriptional factors, including c-jun, signal transducer and activator of 
transcription (STAT3) and nuclear factor of activated T-cell (NFAT) [208-210]. Several 
downstream substrates of MAPK signaling have also been identified, including the Erk1/2-
dependent protein MAPK-activated protein  kinase-1 (MAPKAP-K1), also called p90 ribosomal 
S6kinase (p90RSK) [211] and the p38-dependent protein MAPK-activated protein kinase-2 
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(MAPKAP-K2) [212, 213]. Previous studies have demonstrated ERK1/2- and JNK- MAPK 
activation in skeletal muscle hypertrophy in  response to increased loading in humans and 
rodents [44-47, 214]. The degree of activation of these MAPKs is affected by the mode, intensity 
and duration of the exercise. How muscle overload may regulate MAPK signaling in insulin 
resistant muscle has not been elucidated.  
2.4.5 MicroRNA  
2.4.5.1 MicroRNA transcription, biogenesis and processing 
MicroRNAs (miRNAs) are small ~ 22-nucleotide, non-coding RNAs which are a newly 
emerging class of trans-factors that repress gene expression post-transcriptionally by inhibiting 
translation of target mRNAs through interaction with the 3
’
- untranslated region (3’UTR) of 
target mRNAs [50, 51, 215]. miRNA were first discovered by the Ambros and Ruvkun 
laboratories during genetic screening of developmental progress in C. elegans [216, 217]. Most 
of these miRNAs are located in intergenic regions and are transcribed from their own promoter 
[218, 219]. miRNAs are transcribed as the primary transcript miRNAs (pri-miRNAs), which 
consists of cap structure, Poly (A) tails, and several uridine residues [220]. These pri-miRNAs 
are transcribed by polymerase II (Pol II) before being converted into hairpin intermediates called 
pre-miRNAs (~ 65-nucleotide) and subsequently processed into mature miRNAs. RNase III 
enzymes like drosha and dicer are involved in the maturation process. Drosha is localized in the 
nucleus and has a catalytic domain and a dsRNA-binding domain, whereas dicer is localized in 
the cytoplasm and contains two catalytic domains and additional helicase and PAZ motifs [221, 
222]. After processing in the nucleus pre-miRNAs are exported to  the cytoplasm in a process 
that is mediated by exportin-5 [223]. These pre-miRNAs in the cytoplasm are further processed 
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by dicer before the mature form (22-nucleotide) is incorporated into the RNA-induced silencing 
complex (RISC) [224]. 
2.4.5.2 Mechanism of miRNA action 
There are several mechanisms for protein suppression by miRNA. miRNA can bind to 
mRNA and cause cleavage, destabilization, or degradation of target mRNA. Several miRNAs 
may target a single or multiple mRNAs [225]. The second mechanism is translational repression, 
which is thought to be the main mechanism for repression in mammalian cells [226]. In addition 
to functioning as translational repressors, it has been suggested that miRNA might play a role in 
translational activation. Vasudevan et al., (2008) reported that miRNAs can induce the 
translational activation of target mRNAs in proliferating mammalian cells during cell cycle 
arrest, indicating that the translational regulation by miRNA can be either repressive or 
activating [227]. 
2.4.5.3 MicroRNA functions  
More than 600 human miRNAs have been identified, and it is estimated that they might 
target more than one third of human protein-coding genes [228-230]. Several lines of evidence 
indicate that miRNAs play a key role in a wide variety of biological processes including cell 
proliferation, differentiation, apoptosis as well as in important diseases such as diabetes, cancer, 
cardiovascular disease, HIV/AIDS and muscle wasting [53, 231-233]. 
miRNAs regulate the expression of several transcriptional factors and signaling mediators 
and are thought to play key roles in the development and function of skeletal and cardiac muscle 
[234, 235]. Chen et al., (2006) demonstrated that the muscle-specific miRNAs, miR-1 and miR-
133, regulate skeletal muscle development in an antagonistic manner.  miR-1 promotes muscle 
myogenesis by targeting histone deacetylase 4 (HDAC4), a transcriptional repressor of muscle 
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gene expression, where as miR-133 enhances myoblast proliferation by repressing serum 
response factor (SRF) [53]. Ivey et al., (2008) reported that muscle-specific miR-1 and miR-133 
promote cardiac differentiation from embryonic stem cells [236]. Chen et al., (2010) showed that 
miR-1 and miR-206 are sharply up-regulated during satellite cell differentiation [237]. In 
addition, a recent study by Nakasa et al., (2010) demonstrated enhanced muscle regeneration by 
locally injecting double-stranded (ds) miR-1, miR-133 and 206 in a rat skeletal muscle injury 
model,  likely through the up regulation of the myogenic markers  MyoD1, myogenin and Pax7 
at both mRNA and protein level [238].  
MicroRNA-1 is highly conserved between both invertebrates and vertebrates, and it was 
shown to be highly expressed in muscle tissue [219]. Sokol and Ambros (2005) reported that 
miR-1 mutants of Drosophila have severely deformed musculature [52]. miR-1 has been shown 
to regulate muscle transcription factor MEF2 at the neuromuscular junction in C. elegans [239]. 
Liu et al., (2007) showed that intragenic MEF2-dependent enhancer directs the muscle specific 
expression of miR-1-2 and 133a-1 [240]. Oxidative stress was shown to increase miR-1, and 
miR-133 expression in cardiomyocytes.  miR-1 and miR-133 have produce opposite effects on 
apoptosis. miR-1 promotes apoptosis by repressing the targets HSP60 and HSP70, where as 
miR-133 being anti-apoptotic by repressing the expression of caspase-9 [51]. 
Several lines of evidence suggest that miRNAs lead to aberrant gene expression and that 
these molecules may play a role in the pathophysiology of T2DM [241-247],cardiac hypertrophy 
[248, 249], muscular dystrophy [250-253] and HIV/AIDS [254-256]. For example, silencing 
miR-133 increases glucose uptake in cardiac muscle by increasing glut-4 expression, suggesting  
that miR-133 dysregulation may be involved in the development of T2DM [257]. Thum et al., 
(2008) reported mir-21 antagomir administration in mice with cardiac disease inhibits ERK-
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MAPK activity and cardiac fibrosis [258]. He et al., (2007) reported up regulation of miR-29, 
miR-29a, miR-29b, and miR-29c in muscle, fat and liver of diabetic Goto-Kakizaki (GK) rats 
[259]. Taken together, these studies suggest that muscle-specific miRNAs may play a role in 
muscle development and functional remodeling.  
2.4.5.4 Role of muscle-specific miRNAs in hypertrophy 
The function of muscle-specific miRNAs in embryonic but not adult development has 
been well established. McCarthy and Esser (2007) reported that the expression of muscle-
specific miRNAs is decreased by 50% following 7 days of functional overload in rodent skeletal 
muscle. Interestingly, the transcript levels for both pri-miRNA-1-2 and pri-miRNA-133a-2 along 
with components of the miRNA biogenesis pathway like Drosha and Exportin-5 were 
significantly increased in response to functional overload. This loss of a direct relationship in the 
expression level of pri-miRNAs and their corresponding miR is suggestive of additional 
regulation of miRNA biogenesis during functional overload, which does not appear to involve 
the canonical pathway [7]. How insulin resistance may affect the regulation of these muscle-
specific miRNAs during muscle hypertrophy has, to our knowledge, not been investigated. 
2.4.6 Summary 
Skeletal muscle adaptation to increased load is a complex process that involves activation 
of several intracellular signaling cascades to reprogram gene expression and to sustain muscle 
performance. mTOR and its downstream effectors play a critical role in load induced 
hypertrophy by regulating protein synthesis at multiple levels. AMPK and PKR are two 
important negative regulators of growth that have been shown to inhibit protein synthesis 
through the down regulation of mTOR signaling. In addition, PKR may also be involved in 
enhancing protein degradation. Stress responsive proteins like the HSPs and MAPKs are also 
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capable of regulating protein synthesis and are involved in skeletal muscle adaptation. miRNAs 
are non-coding RNAs that have been shown to play a role in muscle development, function and 
remodeling. The exact molecular mechanism(s) regulating the activity of these molecules is not 
well understood. Similarly, how insulin resistance may affect the regulation of these intracellular 
signaling proteins and muscle-specific miRNAs during muscle hypertrophy has to our 
knowledge, not been investigated. Elucidating the differences between normal and diabetic 
muscle tissue at the molecular level may be beneficial for exercise and pharmacological 
interventions designed for the treatment of T2DM. 
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CHAPTER III 
The following chapter includes three different research papers describing in detail the research 
experiments conducted to test our hypotheses set forth for specific aims I, II and III of this 
dissertation project.  
 
 
SPECIFIC AIM I: To investigate whether insulin resistance affects the regulation of the mTOR 
signaling during muscle hypertrophy 
PAPER 1 
The following paper corresponds to the specific aim I 
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Impaired overload-induced hypertrophy is associated with diminished mTOR 
signaling in insulin resistant skeletal muscle of the obese Zucker rat 
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Abstract 
Recent data have suggested that insulin resistance may be associated with a diminished 
ability of skeletal muscle to undergo hypertrophy [4]. Here we examine the effects of insulin 
resistance using the OZ  rat with  increased muscle loading on the regulation of the mammalian 
target of rapamycin (mTOR) and its downstream signaling intermediates 70 kDa ribosomal 
protein S6 kinase (p70S6k), ribosomal protein S6 (rpS6), eukaryotic elongation factor 2 (eEF2), 
and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Compared to that observed in LZ  
rats, the degree of soleus muscle hypertrophy as assessed by changes in muscle wet weight (LZ: 
35% vs. OZ: 16%) was significantly less in the OZ rats after 3-weeks of muscle overload (P < 
0.05). This diminished growth in the OZ rats was accompanied by significant impairments in the 
ability of the soleus to undergo phosphorylation of mTOR (Ser2448), p70S6k (Thr389), rpS6 
(Ser235/236) and Akt (Ser473 and Thr308) (P < 0.05). Taken together, these data suggest that 
impaired overload-induced hypertrophy in insulin resistant skeletal muscle may be related to 
decreases in the ability of the muscle to undergo mTOR-related signaling.  
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Introduction 
The obese Zucker (fa/fa) rat (OZ) is commonly used as an animal model
 
for the 
investigation of metabolic syndrome given its proclivity to exhibit severe skeletal muscle
 
insulin 
resistance, hyperglycemia, and hyperlipidemia [55]. Previous data from our laboratory have 
suggested that the capacity of the OZ soleus muscle to undergo hypertrophy in response to 
increased loading is diminished compared to that observed in the LZ rat. Why metabolic 
syndrome may affect the hypertrophic response of muscle is not clear, although we and others 
have noted that insulin resistance is associated with differences in the ability of skeletal muscle 
to activate intracellular signaling cascades in response to alterations in contractile activity [15, 
57, 68, 260].  
It is well accepted that increases in protein synthesis precede skeletal muscle growth [20, 
21]. One critical signaling pathway that has been shown to play a role in controlling protein 
synthesis following increased muscle loading is the mammalian target of rapamycin (mTOR) 
[22, 23]. The regulation of mTOR signaling is complex and is likely influenced by several 
upstream molecules and pathways as previous data have suggested the participation of 
phosphoinositide 3-kinase (PI3K), phosphatase and tensin homologue deleted on chromosome 
10 (PTEN), protein kinase B/ Akt, TSC2 / Tuberin, and raptor  [22, 147, 148, 261-263]. The 
mTOR functions to regulate several physiological functions such as gene transcription, protein
 
metabolism, cell cycle control, and cytoskeleton organization [24, 25]. When active 
(phosphorylated), mTOR is thought to promote protein translation by controlling the activity of 
several downstream effectors, including the 70 kDa ribosomal protein S6 kinase (p70S6k), 
ribosomal protein S6 (rpS6), eIF4E-binding protein 1 (4E-BP1), and eukaryotic elongation factor 
2 (eEF2) [27, 264].  
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 The primary purpose of this study was to determine whether insulin resistance affects the 
ability of skeletal muscle to activate mTOR signaling in response to increased loading. The
 
second purpose was to examine the time course of mTOR signaling during the initial and latter 
phases of muscle adaptation. We hypothesized that overload-induced mTOR signaling would 
differ between normal and insulin resistant muscle. Our data suggest that insulin resistance or 
other co-morbidities may be associated with decreases in the ability of skeletal muscle to activate 
mTOR signaling. Whether these changes alone or in combination with other factors may explain 
why insulin resistance may lead to differences in the capacity of skeletal muscle to undergo 
growth are currently unclear.  
 
 40 
 
Materials and Methods 
 Animal Care. 
 All procedures were performed as outlined in the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
institutional animal use review board of Marshall University. Young male LZ (n=12) and OZ 
(n=12) rats were obtained from the Charles River Laboratories. All animals were 12 wk of age at  
the completion
 
of this study. Rats were housed two per cage in an AAALAC approved vivarium. 
Housing conditions consisted of a 12 H: 12 H dark-light cycle and temperature was maintained 
at 22° ± 2 °C. Animals were provided food and water ad libitum and allowed to recover from 
shipment for at least two weeks before experimentation. During this time the animals were 
carefully observed and weighed weekly to ensure none exhibited signs of failure to thrive, such 
as precipitous weight loss, disinterest in the environment, or unexpected gait alterations.  
Synergist ablation procedure. 
 Unilateral overload of the soleus muscle for 1- and 3-weeks was achieved through the 
surgical ablation of the medial and the proximal two-thirds of the lateral head of the 
gastrocnemius [109].  
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Figure 4: Synergistic ablation procedure: In ablation experiment, a muscle is surgically removed 
(A, B, and C). Here the ablated muscle is the gastrocnemius (C- both heads). 
 
The unilateral ablation model allows within animal comparisons, thus eliminating bias due to 
systemic factors. Rats were anesthetized with a ketamine–xylazine (4 : 1) cocktail (50 mg/kg, 
I/P), and the distal two-thirds of the gastrocnemius muscle were surgically removed from the left 
hindlimb as previously described [109]. A sham (control) operation was performed on the right 
hindlimb. The sham procedure consisted of an incision through the skin, followed by blunt 
isolation of the Achilles tendon and gastrocnemius muscle prior to closure. Animals were active 
immediately after recovering from anesthesia and were checked twice daily during the 7-day 
postoperative period. No signs of postoperative complications (such as infection or undue 
distress) were observed.  
Measurement of blood glucose and serum insulin. 
Animals were fasted for 14-h and blood samples were collected directly just prior to 
animal death. Blood samples were immediately centrifuged at 2000 g for 10 min and the 
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supernatant serum was stored at −80 °C until use. Serum insulin concentration was determined 
using a rat/mouse insulin ELISA kit (Linco Research, Inc., St. Charles, MO, USA) as outlined by 
the manufacturer. Blood glucose was measured using blood glucose meter (Bayer Contour, 
Bayer HealthCare LLC, Tarrytown, NY, USA). 
Tissue collection.  
The soleus muscles were collected 7 days (n = 6 LZ-7 and
 
n = 6 OZ-7) or 21 days (n = 6 
LZ-21 and n = 6 OZ-21) after
 
the synergist ablation. The animals were
 
12 wk old at the time of 
tissue collection. Rats were anesthetized with a ketamine–xylazine (4: 1) cocktail (50 mg/kg, I/P) 
and supplemented as necessary for reflexive response before tissue collections. The soleus 
muscles from both legs were quickly removed, trimmed of excess connective tissue, weighed on 
an analytical balance, frozen in liquid nitrogen, and stored at −80◦C until further analysis.  
Tissue homogenization and determination of protein concentration. 
Muscles were homogenized in a Pierce Tissue Protein Extraction Reagent (T-PER) (10 
mL/g tissue; Rockford, IL, USA) that contained protease inhibitors (P8340, Sigma-Aldrich, Inc., 
St. Louis, MO, USA) and phosphatase inhibitors (P5726, Sigma-Aldrich, Inc., St. Louis, MO, 
USA). After incubation on ice for 30 min, the homogenate was collected by centrifuging at 
12,000 g for 5 min at 4
◦
C. The protein concentration of homogenates was determined via the 
Bradford method (Fisher Scientific, Rockford, IL, USA). Homogenate samples were boiled in a 
Laemmli 2× sample buffer (Sigma-Aldrich, Inc., St. Louis, MO, USA) for 5 min. 
SDS-PAGE and immunoblotting. 
Forty micrograms of total protein from each sample was separated on a 10% PAGEr 
Gold Precast gel (Lonza, Rockland, ME, USA) and then transferred to a nitrocellulose 
membrane. Visual verification of transfer and equal protein loading amongst lanes was 
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accomplished by Ponceau S staining of the membranes. For immunodetection, membranes were 
blocked for 1 h at room temperature in blocking buffer (5% non-fat dry milk in TBS-T (20mM 
Tris-base, 150mM NaCl, 0.05% Tween-20), pH 7.6), serially washed in TBS-T at room 
temperature, then probed with antibodies for the detection of Akt (#9272), phospho-Akt (Ser473) 
(#9271), phospho-Akt (Thr308) (#9275), mTOR (#2972), phospho-mTOR (Ser2448) (#2971), 
p70S6k (#9202), phospho-p70S6k (Thr389) (#9205),  phospho-p70S6k (Thr421/Ser424) 
(#9204), rpS6 (#2217), phospho-rpS6 (Ser235/236) (#4858), 4E-BP1 (#9452), phospho 4E-BP1 
(Thr37/46) (#9459), eEF2 (#2332), phospho-eEF2 (Thr56) (#2331), Raptor (#2280), 
Tuberin/TSC2 (#3612), phospho-Tuberin/TSC2 (Thr1462) (#3617), PTEN (#9552), phospho-
PTEN (Ser380/Thr382/383) (#9552), PI3K (#4257), GAPDH (#2118) (from Cell Signaling 
Technology, Inc., Beverly, MA, USA) and myogenin (M-225) (sc-576), and myo-D (C-20) (sc-
304) (from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Membranes were incubated 
overnight at 4
◦
C in primary antibody buffer (5% BSA in TBS-T, pH 7.6, primary antibody 
diluted 1:1000), followed by washing in TBS-T (3X 5 min each), and incubation with HRP- 
conjugated secondary antibody (anti-rabbit (#7074) or anti-mouse (#7076), Cell Signaling 
Technology, Inc., Danvers, MA, USA) in blocking buffer for 1 h. After removal of the secondary 
antibody, membranes were washed (3X 5 min each) in TBS-T and  protein bands visualized on  
reaction with ECL reagent (Amersham ECL Western Blotting reagent RPN 2106, GE Healthcare 
Bio-Sciences Corp., Piscataway, NJ, USA). Target protein levels were quantified by 
AlphaEaseFC image analysis software (Alpha Innotech, San Leandro, CA, USA) and normalized 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
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Statistical analysis.  
Results are presented as mean + SEM. Data were analyzed using the Sigma Stat 3.5 
statistical program. The effects of insulin resistance on protein phosphorylation were analyzed 
using a two-way ANOVA followed by the Student-Newman-Keuls post-hoc testing where 
appropriate. Differences were considered significant at P < 0.05. 
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Results 
Insulin resistance is associated with skeletal muscle atrophy  
All the animals were 12 weeks of age at the end of the study. The OZ animals had 
significantly higher serum levels of insulin (1.75±.05 ng/ml vs. 0.48±.03 ng/ml; 3.64 fold), and 
blood glucose (226±11 mg/dL vs. 121±10 mg/dL; 1.85 fold) compared to their lean counterparts. 
These results are consistent with the notion that the OZ rats were hyperglycemic and 
hyperinsulinemic (Fig. 5). 
 
Figure 5: Biochemical determination of blood glucose and insulin levels in LZ and OZ 
rats.*Significantly different from LZ animals; n = 12. 
 
The OZ rats exhibited a significantly higher body weight than the LZ at both 7 and 14 
days of observation (464 ± 12 g vs. 302 ± 3 g at 7 days; P < 0.05; 460±26 g vs. 289±10 g at 21 
days; P < 0.05). Soleus muscle wet weights were significantly lower in the OZ compared to the 
LZ (128 ± 11 mg vs. 150±6 mg at 7 days; P < 0.05; 128.0±6.5 mg vs. 141.0±8.3 mg at 21 days; 
P < 0.05; Fig. 6).   
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Figure 6: Muscle wet weight to-body weight ratios in control and loaded (7- or 21-days) soleus 
muscles of lean Zucker rat and obese Zucker rats; n = 6. *Significantly different from lean 
control value, P < 0.05. †Significantly different from contralateral control, P < 0.05. 
Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese 
Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese overload. 
 
Insulin resistance is associated with a diminished hypertrophic response that is characterized by 
decreases in the activation of mTOR related signaling.  
Muscle overload increased soleus muscle mass to a similar extent in the LZ and OZ 
animals at 7 days (39% vs. 36%) but the degree of overload-induced muscle growth at 21days 
was greater in the LZ compared to OZ animals (35% vs. 16%; P < 0.05; Fig. 6). According to 
our immunoblot analysis, the phosphorylation of mTOR (Ser2448) and p70S6k (Thr389) in 
overloaded muscles was elevated relative to the contralateral control after 7 and 21 days of 
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overload in the LZ rats and after 7 days of overload in the OZ rats (P < 0.05; Figs. 7B, 8B).  The 
phosphorylation of p70S6k (Thr421/Ser424) was significantly higher in overloaded muscles of 
both LZ and OZ rats after 7 and 21 days (P < 0.05; Fig. 8C). Overload increased the amount of 
rpS6 protein in both the LZ and OZ rats at 7 and 21 days of observation (P < 0.05; Fig. 9A). 
Conversely, the phosphorylation of rpS6 (Ser235/236) in overloaded muscles was elevated after 
7 and 21 days of overload in LZ animals but only at the 7 day time point in the OZ rats (P < 
0.05; Fig. 9B). The phosphorylation eEF2 (Thr56) was higher in both the LZ and OZ rats after 7 
days of overload (P < 0.05) (Fig. 10B). Overload did not alter the amount of phosphorylated 4E-
BP1 in either the LZ or OZ animals (Fig. 11B).  
 
 
Figure 7: Immunoblot analysis of the mammalian target of rapamycin (mTOR) (A) protein 
content and (B) phosphorylation at Ser
2448
 in control and overloaded soleus muscles of LZ and 
OZ. Data are expressed as integrated optical density (IOD) × band area and expressed in 
arbitrary units relative to the amount of GAPDH; n = 6. †Significantly different from 
contralateral control muscle, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of 
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loading; LZ, lean Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese 
control; OO, obese overload. 
 
 
Figure 8: Immunoblot analysis of the 70 kDa ribosomal protein S6 kinase (p70S6k) (A) protein 
content, (B) phosphorylation at Thr
389
, and (C) phosphorylation at Thr
421
/Ser
424 
in control and 
overloaded soleus muscles of LZ and OZ. Data are expressed as integrated optical density (IOD) 
× band area and expressed in arbitrary units relative to the amount of GAPDH; n = 6. 
†Significantly different from contralateral control muscle, P < 0.05. Abbreviations: 7d, 7 days of 
loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese Zucker; LC, lean control; LO, lean 
overload; OC, obese control; OO, obese overload. 
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Figure 9: Immunoblot analysis of the ribosomal protein S6 (rpS6) (A) protein content and (B) 
phosphorylation at Ser
235/236 
in control and loaded soleus muscles of LZ and OZ. Data are 
expressed as integrated optical density (IOD) × band area and expressed in arbitrary units 
relative to the amount of GAPDH; n = 6. †Significantly different from contralateral control 
muscle, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
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Figure 10: Immunoblot analysis of the eukaryotic factor 2 (eEF2) (A) protein content and (B) 
phosphorylation at Thr
56 
in control and loaded soleus muscles of LZ and OZ. Data are expressed 
as integrated optical density (IOD) × band area and expressed in arbitrary units relative to the 
amount of GAPDH; n = 6. †Significantly different from contralateral control muscle, P < 0.05. 
Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese 
Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese overload. 
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Figure 11: Immunoblot analysis of the eukaryotic initiation factor 4E-binding protein 1 (4E-
BP1) (A) protein content and (B) phosphorylation at Thr
37/46 
in control and loaded soleus 
muscles of LZ and OZ. Data are expressed as integrated optical density (IOD) × band area and 
expressed in arbitrary units relative to the amount of GAPDH. n = 6. †Significantly different 
from contralateral control muscle, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days 
of loading; LZ, lean Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese 
control; OO, obese overload. 
Alterations in regulation of different possible upstream regulators of mTOR signaling in the 
soleus muscle of OZ with overload.  
To examine the effect of insulin resistance on the activation of different mTOR regulators 
with overload, we compared the protein content and phosphorylation of Akt, PTEN, TSC2 / 
Tuberin, and raptor between control and overloaded muscles. Similar to our findings for mTOR, 
the amount of phosphorylated Akt (Thr308) and Akt (Ser473) was increased at 7 and 21 days of 
overload in the LZ rats, where as it was only elevated after 7 days of overload in the OZ rats (P 
< 0.05; Fig. 12). The muscle content and phosphorylation of PTEN was increased by muscle 
overload in the LZ and OZ animals at both 7 and 21 days (P < 0.05; Fig. 13). The protein 
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content of Tuberin / TSC2 was higher in LZ and OZ animals after 7 days of overload (P < 0.05) 
and at 21 days in the OZ rats (P < 0.05; Fig. 14). The phosphorylation of Tuberin / TSC2 
(Thr1462) was diminished in LZ rats at 7 and 21 days of overload and in the OZ animals after 7 
days of increased loading (P < 0.05; Fig. 14). Muscle loading did not alter the expression of 
raptor in either the LZ or OZ animals (Fig. 15).  
 
Figure 12: Immunoblot analysis of the Akt (A) protein content, (B) phosphorylation at Thr
308
, 
and (C) phosphorylation at Ser
473 
in control and loaded soleus muscles of LZ and OZ. Data are 
expressed as integrated optical density (IOD) × band area and expressed in arbitrary units 
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relative to the amount of GAPDH; n = 6.*Significant difference from respective LZ control 
muscle, P < 0.05. †Significantly different from contralateral control muscle, P < 0.05. 
 
 
 
Figure 13: Immunoblot analysis of the phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) (A) protein content and (B) phosphorylation at Ser
380
/Thr
382/383
, in 
control and loaded soleus muscles of LZ and OZ. Data are expressed as integrated optical density 
(IOD) × band area and expressed in arbitrary units relative to the amount of GAPDH; n = 6. 
†Significantly different from contralateral control muscle, P < 0.05. Abbreviations: 7d, 7 days of 
loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese Zucker; LC, lean control; LO, lean 
overload; OC, obese control; OO, obese overload. 
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Figure 14: Immunoblot analysis of the Tuberin/TSC2 (A) protein content and (B) 
phosphorylation at Thr
1462
, in control and loaded soleus muscles of LZ and OZ. Data are 
expressed as integrated optical density (IOD) × band area and expressed in arbitrary units 
relative to the amount of GAPDH; n = 6.*Significant difference from respective LZ control 
muscle, P < 0.05. †Significantly different from contralateral control muscle, P < 0.05. 
Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese 
Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese overload. 
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Figure 15: Immunoblot analysis of raptor protein content in control and loaded soleus muscles 
of LZ and OZ. Data are expressed as integrated optical density (IOD) × band area and expressed 
in arbitrary units relative to the amount of GAPDH; n = 6. 
 
Overload did not alter expression of myogenic regulatory factors (MRFs). 
 Given the potential role that MRF may play in the regulation of satellite activation and 
muscle hypertrophy [57, 265], we next examined the regulation of myogenin and myoD with 
overload. Overload of the soleus muscles did not alter the myogenin and myoD expression in 
either the lean or obese Zucker rats (Fig. 16).  
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Figure 16: Supplemental Figure - Immunoblot analysis of myoD and myogenin expression in 
control and loaded soleus muscles of LZ and OZ. Data are expressed as integrated optical density 
(IOD) × band area and expressed in arbitrary units relative to the amount of GAPDH; n = 6. 
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Discussion 
Previous work by our laboratory has demonstrated that the degree of soleus muscle 
hypertrophy following eight weeks of compensatory overload appears to be blunted in the insulin 
resistant OZ rat compared to its lean counterpart [4]. Here we examine the time course of muscle 
growth and the activation of mTOR and mTOR related signaling at one- and three-weeks of 
overload in an effort to better understand why muscle hypertrophy may be diminished in the OZ 
rat. Our data suggest that insulin resistance may affect the ability of slow muscle to maintain 
activation of mTOR related signaling after the first week of loading.  
mTOR has been suggested to be an important regulator of muscle growth as studies 
showing inhibition of mTOR by the drug rapamycin almost completely inhibit the hypertrophic 
response [22]. Here we demonstrated that the phosphorylation (activation) of mTOR appears to 
be similar after one week of overload but significantly less in the overloaded OZ rat compared to 
LZ rat after three weeks of overload (Fig. 7). This latter finding is consistent with our data 
demonstrating that the insulin resistant soleus exhibits a reduced ability to undergo hypertrophy 
following eight weeks of mechanical overload [4]. To examine how this defect in mTOR 
signaling might affect the regulation of molecules thought to be involved in controlling protein 
translation we next examined how insulin resistance affected the phosphorylation of eukaryotic 
initiation factor (eIF) 4E
 
binding protein-1 (4E-BP1) and p70S6k in response to increased muscle 
loading. As expected from our mTOR data, the phosphorylation of the mTOR substrates, 4E-
BP1 and p70S6k, was significantly less in the OZ rat compared to that observed in the LZ rat 
(Figs. 8, 11). How these differences in the activation (phosphorylation) of 4E-BP1 and p70S6k 
may affect the hypertrophic response of the insulin resistant soleus is currently unclear. 
However, other work has demonstrated convincingly that the phosphorylation of these molecules 
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is highly correlated with the degree of muscle hypertrophy [30, 266]. The underlying molecular 
mechanisms for these alterations remain unclear. However, it is interesting to note that other 
studies have demonstrated that the phosphorylation of p70S6k in response to insulin [267-269] 
and increased muscle loading [68] may be altered in the diabetic rat model.  
To confirm these data, we also examined the regulation of ribosomal protein S6 (rpS6), 
which is a substrate of p70s6k [270].  It has been shown that phosphorylation of rpS6 by p70S6k 
correlates with an increase in translation, particularly of mRNAs with an oligopyrimidine tract in 
their 5’ untranslated regions [271]. Consistent with our findings for p70S6k, we found that the 
degree of rpS6 phosphorylation at Ser 235/236 following three weeks of overload was 
diminished in the OZ compared to their lean counterparts (Fig. 9).  Further, we examined the  
regulation of eukaryotic elongation
 
factor 2 (eEF2) which is a GTP-binding protein that functions 
to repress the translocation step of elongation when in its nonphosphorylated state [176]. We 
found similar changes in the expression and phosphorylation of eEF2 following overload in both 
lean and obese animals (Fig. 10). These data suggest that the attenuation of hypertrophy in 
insulin resistant muscle may not be due to differences in the regulation of the elongation phase of 
the protein translation process.    
Like mTOR and p70S6k, the activation of protein kinase B / Akt is thought to be required 
for muscle hypertrophy as the over expression of constitutively active Akt results in increased 
p70S6k phosphorylation, glycogen accumulation, and muscle fiber hypertrophy [272]. Previous 
data has demonstrated that phosphorylation of serine and threonine residues within the carboxyl 
terminal hydrophobic domain (Ser473) and catalytic domain (Thr308) are necessary for full 
activation of Akt kinase activity [273]. Compared to that seen in the LZ, the ability of the soleus 
to activate (phosphorylation at both Ser473 and Thr308) Akt in the OZ appears to be diminished 
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(Fig. 12). How this might affect the activation of other signaling molecules is currently unclear; 
however, it is likely that Akt can influence the activity of mTOR through its ability to 
phosphorylate the product of the tuberous sclerosis
 
complex TSC2 gene, also termed tuberin. 
Tuberin is a tumor suppressor that inhibits mTOR when unphosphorylated and is involved in the 
regulation of cell proliferation and tumor development [147, 148]. Here we demonstrate that the 
Akt-dependent phosphorylation of tuberin (Thr1462) is diminished in the LZ rat while it is 
unaltered in OZ rat following three weeks of overload (Fig. 14). Because decreased tuberin 
phosphorylation should lead to a decrease in mTOR activity, it is likely that the differences in 
mTOR phosphorylation we see between models is not due to alterations in TSC2 regulation. 
Similar to tuberin, raptor is also thought to interact with mTOR where it acts to increase the 
phosphorylation of p70S6k and 4E-BP1 [274]. Unlike with tuberin, we did not observe any 
difference in the amount of raptor between models or with overload (Fig. 15) suggesting that the 
attenuation of mTOR activity in insulin resistant muscle may not be due to differences in raptor 
regulation. 
The activity of PI3K/Akt/mTOR signaling is thought to be negatively regulated by the 
tumor suppressor protein, phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
[263]. Like our findings for raptor, we found similar increases in the amount of PTEN 
phosphorylation following overload in both the lean and obese rats (Fig. 13). This finding is 
quite interesting as it suggests that PTEN is unlikely to play a role in explaining why insulin 
resistant muscle exhibits differences in its ability to activate Akt and mTOR following increased 
muscle loading. Why the magnitude of load-induced mTOR signaling may differ with insulin 
resistance is not clear. In addition to Akt, raptor and TSC2, the activity of mTOR is also 
influenced by a myriad of other molecules including AMP-activated protein kinase (AMPK), 
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rictor, REDD2, phospholipase D (PLD), and possibly others [275-280]. Recent in vitro and in 
vivo data has suggested that AMPK may inhibit protein synthesis through its ability to suppress 
mTOR activation [22, 34, 135]. Consistent with this finding, work by Thomson and Gordon has 
demonstrated that the diminished overload-induced hypertrophy seen in aged skeletal muscle is 
associated with AMPK hyperphosphorylation [180]. Further experiments to investigate whether 
a similar relationship between AMPK activation and the degree of muscle growth is present in 
insulin-resistant muscle will likely add to our understanding of what role this molecule may play 
in modulating muscle growth. In an effort to explore other possible mechanisms for the 
attenuated hypertrophy we observe in the OZ animals, we next examined if muscle overload was 
associated with alterations in the amount of myogenic regulatory factors, MyoD and myogenin, 
which have been posited to be involved in regulating satellite cell activation. Consistent with 
previous work examining the myogenin and myoD levels in rat soleus muscle after 4 weeks of 
surgical overload [281], we observed no changes in the amount of myogenin and myoD with 
overload in either the LZ and OZ animals (Fig. 16).  It is also possible that differences in the 
degree of animal activity may also have played a role in the differential hypertrophic response 
between the LZ and OZ rats. Because the hypertrophy stimulus in the synergistic ablation model 
are dependent, at least in part, on animal activity, it is possible that the soleus muscles of the less 
active obese animals [282] were loaded to a lesser degree than their lean counterparts. Whether 
this was actually the case cannot be determined from our data. Nonetheless, it is also worthy to 
point out that the greater body mass of the obese Zucker rats likely produced a greater overload 
stimulus for muscle growth on the weight-bearing
 
muscles. To address these possibilities, future 
studies employing other animal models that do not differ in their amount of activity or body 
weight may be warranted.  
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Figure 17: Schematic summarizing the differences in load-induced signaling between the lean 
and obese Zucker rats after 21 days of overload. Molecules shown in the dark-shaded, medium-
shaded, and empty circles represent no change, complete activation or inactivation with respect 
to control leg, and differences in activation between animal models, respectively. Impaired 
hypertrophy in obese Zucker rats is associated with an attenuated activation of Akt, mTOR, 
p70S6k, and rpS6 
 
In summary, the data of the present study suggest that insulin resistance may be 
associated with a decrease in the ability of the soleus muscle to undergo muscle hypertrophy and 
that this finding may be related to differences in mTOR, p70S6k, Akt, and rpS6 signaling (Fig. 
17). These findings are novel, as they are the first to demonstrate impaired mTOR related 
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signaling in direct conjunction with attenuated overload induced hypertrophy in insulin-resistant 
skeletal muscle. Additional studies designed to directly inhibit or activate these signaling 
molecules, as well as to explore the other possible mechanism(s) e.g. AMPK signaling during 
muscle adaptation, will be needed to increase our understanding of the exact mechanism(s) 
involved and the clinical ramifications for an ever increasing diabetic population.  
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SPECIFIC AIM II: To investigate whether insulin resistance affects the regulation of the 
AMPK and PKR during muscle hypertrophy. 
PAPER 2 
The following paper corresponds to the specific aim II. 
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Attenuation in overload-induced hypertrophy in insulin- resistant muscle is 
associated with hyperphosphorylation of AMPK and dsRNA-dependent protein kinase 
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Abstract 
Previous data have suggested that diminished hypertrophy in insulin-resistant skeletal 
muscle may result, at least in part, from decrements in mammalian target of rapamycin (mTOR) 
signaling [283]. Here we investigate whether alterations in AMP-activated protein kinase 
(AMPK) and dsRNA-dependent protein kinase (PKR)-dependent signaling may also play a role 
in this process. Compared to that observed in LZ rats, the phosphorylation of AMPKα at Thr172 
and its upstream activator calcium/calmodulin-activated protein kinase (CaMKII) at Thr286 were 
higher in the insulin resistant obese Zucker (OZ) soleus (P < 0.05). The activation 
(autophosphorylation) levels of PKR, PKR dependent phosphorylation of eIF2α at Ser51 and p38 
MAP kinase were significantly higher in OZ rats compared to LZ rats (P < 0.05). Taken 
together, these results suggest that insulin resistance attenuates overload-induced skeletal muscle 
hypertrophy through the activation of AMPK and PKR leading to inhibition of mTOR signaling 
and phosphorylation of eIF2α and depression of protein synthesis, together with PKR mediated 
p38 MAP kinase activation and increased protein degradation.  
 
KEY WORDS: Insulin resistance; obese Zucker rat; skeletal muscle; AMPK; PKR  
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Introduction 
Skeletal muscle is a primary consumer of blood glucose and is thought to participate in 
the control of blood glucose levels, where as other studies have demonstrated that increases in 
muscle mass or muscle hypertrophy are associated with blood glycemic control [284-286]. It has 
been hypothesized that the regulation of muscle growth is dependent upon the balance between 
protein synthesis and degradation with increases in muscle mass occurring when protein 
accretion is favored over its breakdown. The molecular mechanism(s) controlling muscle 
hypertrophy are not well understood.  
Previous studies from our laboratory using the obese Zucker (OZ) rat have demonstrated 
that insulin resistance is associated with a diminished ability of skeletal muscle to undergo 
hypertrophy that may be caused, at least in part, by decrements in activation of the mammalian 
target of rapamycin (mTOR) [4, 287]. Why insulin resistance may be associated with differences 
in the regulation of mTOR signaling is currently unclear but it is possible that these differences 
may be related to events thought to reside upstream of the mTOR molecule. In this regard, one 
protein of potential interest may be the 5'
_
AMP-activated protein kinase (AMPK). Recent data 
suggest that AMPK may function as a master sensor of cellular energy balance and that it may be 
a negative regulator of protein synthesis [26, 34]. AMPK is a heterotrimeric complex consisting 
of one catalytic subunit (α) and two non catalytic regulatory (β and γ) subunits, whose activation 
is controlled through phosphorylation of the α subunit at Thr172 [168]. It has been shown that 
AMPK may inhibit protein synthesis through its ability to suppress mTOR activation [22, 34, 
135, 288, 289]. The factors controlling the activity of AMPK have not been fully elucidated, 
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however, it is thought that protein tumor suppressor LKB1 kinase [35, 169, 170], 
calcium/calmodulin-activated protein kinase (CaMKII) [36, 171], and transforming growth 
factor-β-activated kinase-1 (TAK1), a member of the mitogen-activated protein (MAP) kinase 
family, may be involved  [37, 172]. In addition to AMPK signaling, other recent in vitro and in 
vivo studies have suggested that  dsRNA-dependent protein kinase (PKR) can also play a role in 
the inhibition of protein synthesis [33, 185, 290, 291]. PKR when activated phosphorylates eIF2α 
at Ser-51 [290], which in turn leads to translational inhibition and presumably, a decrease in 
protein synthesis [38]. In addition to its potential effect on protein synthesis, PKR may also have 
a hand in controlling the ubiquitin proteolytic pathway through the activation of p38 MAP kinase 
[39, 40]. How insulin resistance may affect the regulation of PKR during muscle hypertrophy has 
to our knowledge not been investigated.  
Using the same animals and tissues used in our previous work [287], here we investigate 
whether insulin resistance affects the regulation of AMPK and PKR, during muscle hypertrophy. 
We hypothesize that the attenuation of muscle growth and mTOR activation following increased 
muscle loading observed with insulin resistance may be related to alterations in AMPK and PKR 
signaling.  
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Materials and Methods 
Materials. 
Primary antibodies against AMPKα (#2532), AMPKα1 (#2795), AMPKα2 (#2757), 
AMPKβ1/2 (#4150), phospho-AMPKα (Thr172) (#2535), LKB1 (#3050), phospho-LKB1 
(Ser428)(#3482), CaMKII (#3362), phospho-CaMKII (Thr286)(#3361), TAK1 (#4505), 
phospho-TAK1 (Thr184/187) (#4531), eIF2α (#9722), phospho-eIF2α (Ser51)(#3597), GSK-3β 
(#9315), phospho-GSK-3β  (Ser9) (#9336), p38 MAP kinase (#9212), phospho-p38 MAP kinase 
(Thr180/Tyr182)(#9216), Ubiquitin (#3936), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH,#2118), secondary antibodies conjugated with horseradish peroxidase (HRP) (anti-
rabbit (#7074) or anti-mouse (#7076)) were purchased from Cell Signaling Technology (Beverly, 
MA). PKR (sc-708) and phospho-PKR (Thr446) (sc-101783) were from Santa Cruz 
Biotechnology (Santa Cruz, CA). The Laemmli 2 × sample buffer was from Sigma-Aldrich (St. 
Louis, MO). Pierce Tissue Protein Extraction Reagent (T-PER), Pierce 660nm protein assay 
reagent (#22660), GE Healthcare Amersham ECL™ Western Blotting Detection Reagents 
(RPN2106) and Advance Western Blotting Detection Kit (RPN2135) were from Thermo Fisher 
Scientific Inc. (Rockford, IL). The PAGEr Gold Precast gels (10%) were purchased from Lonza 
(Rockland, ME). 
Animal Care. 
 All procedures were performed as outlined in the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
institutional animal use review board of Marshall University. The animals and tissues used in 
this study have been previously examined [287]. Young male LZ (n=12) and OZ (n=12) rats 
were obtained from the Charles River Laboratories. All animals were 12 wk of age at the 
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completion
 
of this study. Rats were housed two per cage in an AAALAC approved vivarium. 
Housing conditions consisted of a 12 H: 12 H dark-light cycle and temperature was maintained 
at 22° ± 2°C. Animals were provided food and water ad libitum and allowed to recover from 
shipment for at least two weeks before experimentation. During this time the animals were 
carefully observed and weighed weekly to ensure none exhibited signs of failure to thrive, such 
as precipitous weight loss, disinterest in the environment, or unexpected gait alterations.  
Synergist ablation procedure. 
 Unilateral overload of the soleus muscle for 1 and 3 weeks was achieved through the 
surgical ablation of the medial and the proximal two-thirds of the lateral head of the 
gastrocnemius [109]. The unilateral ablation model allows within animal comparisons, thus 
eliminating bias due to systemic factors. Rats were anesthetized with a ketamine–xylazine (4 : 1) 
cocktail (50 mg/kg, I/P) and, the distal two-thirds of the gastrocnemius muscle were surgically 
removed from the left hindlimb as previously described [109]. A sham (control) operation was 
performed on the right hindlimb. The sham procedure consisted of an incision through the skin, 
followed by blunt isolation of the Achilles tendon and gastrocnemius muscle prior to closure. 
Animals were active immediately after recovering from anesthesia, and were checked twice daily 
during the 7 day postoperative period. No signs of infection or other complications were 
observed postoperatively.  
Tissue collection.  
Soleus muscles were collected 7 days (n = 6 LZ-7 and
 
n = 6 OZ-7) or 21 days (n = 6 LZ-
21 and n = 6 OZ-21) after
 
the synergist ablation procedure. Animals were
 
12 wk old at the time 
of tissue collection. Rats were anesthetized with a ketamine–xylazine (4: 1) cocktail (50 mg/kg, 
I/P) and supplemented as necessary for reflexive response. Soleus muscles from both legs were 
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quickly removed, trimmed of excess connective tissue, weighed on an analytical balance, frozen 
in liquid nitrogen, and stored at −80◦C until further analysis.  
Tissue protein extraction. 
Muscles were homogenized in a Pierce Tissue Protein Extraction Reagent (T-PER) (10 
mL/g tissue; Rockford, IL, USA) that contained protease inhibitors (P8340, Sigma-Aldrich, Inc., 
St. Louis, MO, USA) and phosphatase inhibitors (P5726, Sigma-Aldrich, Inc., St. Louis, MO, 
USA). After incubation on ice for 30 min, the homogenate was collected by centrifuging at 
12,000 g for 5 min at 4
◦
C. The protein concentration of the homogenates was determined via the 
Bradford method (Fisher Scientific, Rockford, IL, USA). Homogenate samples were boiled in 
Laemmli 2× sample buffer (Sigma-Aldrich, Inc., St. Louis, MO, USA) for 5 min prior to SDS-
PAGE. 
SDS-PAGE and immunoblotting. 
Forty micrograms of total protein from each sample was separated on a 10% PAGEr 
Gold Precast gel (Lonza, Rockland, ME, USA) and then transferred to a nitrocellulose 
membrane. Visual verification of transfer and equal protein loading amongst lanes was 
accomplished by Ponceau S staining of the membranes. Immunodetection of antigens was 
performed as described previously [16, 68]. Briefly, membranes were blocked for 1 h at room 
temperature in blocking buffer (5% non-fat dry milk in TBS-T (20mM Tris-base, 150mM NaCl, 
0.05% Tween-20), pH 7.6), serially washed in TBS-T at room temperature, then incubated 
overnight at 4
◦
C in primary antibody buffer (5% BSA in TBS-T, pH 7.6, primary antibody 
diluted 1:1000), followed by washing in TBS-T (3X 5 min each), and incubation with HRP- 
conjugated secondary antibody (anti-rabbit (#7074) or anti-mouse (#7076), Cell Signaling 
Technology, Inc., Danvers, MA, USA) in blocking buffer for 1 h. After removal of the secondary 
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antibody, membranes were washed (3X 5 min each) in TBS-T and  protein bands visualized on 
reaction with ECL reagent (Amersham ECL Western Blotting reagent RPN 2106, GE Healthcare 
Bio-Sciences Corp., Piscataway, NJ, USA). Target protein levels were quantified by 
AlphaEaseFC image analysis software (Alpha Innotech, San Leandro, CA, USA) and normalized 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Statistical analysis.  
Results are presented as mean + SE. Data were analyzed using the Sigma Stat 3.5 
statistical program. The effects of insulin resistance on protein phosphorylation were analyzed 
using a two-way ANOVA followed by the Student-Newman-Keuls post-hoc testing where 
appropriate. Values of P < 0.05 were considered to be statistically significant.  
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Results 
Insulin resistance is associated with a diminished hypertrophic response that is characterized by 
hyperphosphorylation of AMP-activated protein kinase (AMPK) 
As outlined previously, the OZ rat exhibited a significantly higher body weight than the 
LZ at both 7 and 14 days of observation (464 ± 12 gm vs. 302 ± 3 gm at 7 days; P < 0.05; 
460±26 vs. 289±10 mg at 21 days; P < 0.05) and  soleus muscle wet weights were 
significantly lower in the OZ compared to the LZ (128 ± 11 mg vs. 150±6 mg; at 7 days; P < 
0.05; 128.0±6.5 vs. 141.0±8.3 mg at 21 days; P < 0.05)  [287]. To examine the effect of 
insulin resistance on the regulation of AMPK with overload, we compared the protein content of 
different AMPK isoforms and phosphorylation of AMPKα at Thr172. Muscle loading did not 
alter the expression of AMPK isoforms (α1, α2, β1 and β2) in either the LZ or OZ animals (Fig. 
18). The phosphorylation of AMPKα at Thr172 was diminished in both LZ and OZ animals after 
7 days of increased loading, while it was significantly increased in OZ rats after 21 days of 
overload (P < 0.05; Fig. 18). 
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Figure 18: (A) AMP-activated protein kinase (AMPK) subunit protein content and (B) 
Immunoblot analysis of the AMPKα at Thr172 in control and overloaded soleus muscles of LZ 
and OZ. Data are expressed as integrated optical density (IOD) × band area and expressed in 
arbitrary units relative to the amount of GAPDH; n = 6. †Significantly different from 
contralateral control muscle, *Significantly different from lean control value, P < 0.05. 
Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese 
Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese overload. 
Effect of overload on different potential upstream regulators of AMPK signaling in the soleus 
muscle of LZ and OZ rats  
To examine the effect of insulin resistance on the activation of different potential 
upstream regulators of AMPK with overload, we compared the protein content and 
phosphorylation of LKB1, CaMKII, and TAK1 between control and overloaded muscles. The 
protein expression for LKB1 was increased by muscle overload in the LZ and OZ animals at 7 
days, and the phosphorylation of LKB1 at Ser428 was increased by muscle overload in both LZ 
and OZ animals at both 7 and 21 days (P < 0.05; Fig. 19, Panels A, B). The protein expression 
for CaMKII was unaltered with muscle overload in both LZ and OZ animals, where as the 
 74 
 
phosphorylation levels of CaMKII was significantly higher in OZ rat with overload at both 7 and 
21 days (P < 0.05; Fig. 19, Panels C, D).  The amount of TAK1 protein was increased by muscle 
overload in the LZ and OZ animals at 7 days and the amount of phosphorylated TAK1 at 
Thr184/187 was increased at 7 and 21 days of overload in the LZ rats, while it was elevated only 
after 7 days of overload in the OZ rats (P < 0.05; Fig. 19, Panels E, F). 
 
Figure 19: Immunoblot analysis of the different upstream regulators of AMPK , LKB1 (A) 
protein content and (B) phosphorylation at Ser428, CaMKII (C) protein content and (D) 
phosphorylation at Thr286, and CaMKII (E) protein content and (F) phosphorylation at 
Thr184/187 in control and overloaded soleus muscles of LZ and OZ. Data are expressed as 
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integrated optical density (IOD) × band area and expressed in arbitrary units relative to the 
amount of GAPDH; n = 6. †Significantly different from contralateral control muscle, * 
Significantly different from lean control value, P < 0.05. 
The diminished hypertrophic response seen in insulin resistant animals is associated with the 
activation of PKR dependent signaling 
To examine the effect of insulin resistance on the activation of PKR dependent signaling 
with overload, we compared the protein content and phosphorylation of PKR, eIF2α, and p38 
MAP kinase between control and overloaded muscles. The total amount of PKR protein in 
overloaded muscles was elevated relative to the contralateral control after 7 days of overload in 
the LZ rats and after 7 and 21 days of overload in the OZ rats (P < 0.05; Fig. 20).  Conversely, 
the phosphorylation of PKR at Thr446 was decreased at both 7 and 21 days of overload in the LZ 
rats, where as it was decreased after 7 days of overload and significantly elevated after 21 days 
overload in the OZ rats (P < 0.05; Fig. 20). Similar to our findings for PKR, the amount of 
phosphorylated eIF2α at Ser51 was decreased at both 7 and 21 days of overload in the LZ rats 
while it was decreased after 7 days of overload but significantly elevated after 21 days overload 
in the OZ rats (P < 0.05; Fig. 21). Muscle loading did not alter the expression of eIF2α and p38 
MAP kinase in either the LZ or OZ animals (Figs. 21 and 23). The phosphorylation levels of p38 
MAP kinase at Thr180/Tyr182 in overloaded muscles were elevated relative to the contralateral 
control after 7 days of overload in the LZ rats and after 7 and 21 days of overload in the OZ rats 
(P < 0.05; Fig. 23). The ubiquitinated protein levels were increased in both LZ and OZ rats after 
7 days and significantly elevated only in the OZ rats after 21 days overload (P < 0.05; Fig. 24).   
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Figure 20: Immunoblot analysis of the dsRNA-dependent protein kinase (PKR) (A) protein 
content and (B) phosphorylation at Thr446, in control and loaded soleus muscles of LZ and OZ. 
Data are expressed as integrated optical density (IOD) × band area and expressed in arbitrary 
units relative to the amount of GAPDH; n = 6. †Significantly different from contralateral control 
muscle, P < 0.05. 
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Figure 21: Immunoblot analysis of the eIF α (A) protein content and (B) phosphorylation at 
Ser51, in control and loaded soleus muscles of LZ and OZ. Data are expressed as integrated 
optical density (IOD) × band area and expressed in arbitrary units relative to the amount of 
GAPDH; n = 6. †Significantly different from contralateral control muscle, P < 0.05. 
 
 
Figure 223: Immunoblot analysis of the p38 MAP kinase (A) protein content and (B) 
phosphorylation at Thr180/Tyr182, in control and loaded soleus muscles of LZ and OZ. Data are 
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expressed as integrated optical density (IOD) × band area and expressed in arbitrary units 
relative to the amount of GAPDH; n = 6. †Significantly different from contralateral control 
muscle, P < 0.05. 
 
 
Figure 234: Immunoblot analysis of the ubiquitinated protein levels, in control and loaded soleus 
muscles of LZ and OZ rats. Data are expressed as integrated optical density (IOD) × band area 
and expressed in arbitrary units relative to the amount of GAPDH; n = 6. †Significantly different 
from contralateral control muscle, P < 0.05. 
Effect of overload on regulation of GSK-3β in the soleus muscle of LZ and OZ rats  
Given the role of GSK-3β in suppression of protein synthesis through its ability to inhibit 
the translational initiation complex [292], we next examined the regulation of GSK-3β with 
overload. The muscle content and phosphorylation of GSK-3β on Ser9 was increased by muscle 
overload in the LZ and OZ animals at 7 days. Conversely, after 21 days of overload the 
phosphorylation of GSK-3β on Ser9 (Ser235/236) was elevated only in LZ animals (P < 0.05; 
Fig. 22) 
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Figure 242: Immunoblot analysis of the GSK-3β (A) protein content and (B) phosphorylation at 
Ser9, in control and loaded soleus muscles of LZ and OZ. Data are expressed as integrated 
optical density (IOD) × band area and expressed in arbitrary units relative to the amount of 
GAPDH; n = 6. †Significantly different from contralateral control muscle, * Significantly 
different from lean control value, P < 0.05. 
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Discussion 
The phosphorylation of AMPK at Thr172 is thought to lead to an inhibition of protein 
synthesis and has been found to be negatively correlated with the degree of muscle hypertrophy 
in the overloaded rat [180]. Here we found that the phosphorylation of Thr172 appears to be 
similar after one week of overload in the LZ and OZ animals but that it is significantly higher in 
the overloaded OZ rat compared to LZ rat after three weeks of overload (Fig. 18). These latter 
data are consistent with our previous report demonstrating a decrease in the ability of the OZ to 
undergo muscle hypertrophy following overload [4]. In addition, because the AMPK is thought 
to inhibit the activity of mTOR [34, 135], the increased AMPK phosphorylation (activation) 
observed in the OZ animals may help to explain why mTOR signaling may be decreased in the 
OZ soleus following muscle overload.  
The mechanism(s) whereby insulin resistance may lead to an increase in AMPK 
phosphorylation during muscle overload is currently unknown. Recent studies have suggested 
that the activity of AMPK may be regulated by its upstream kinases, LKB1 [170, 293], CaMKII  
[294, 295],  and TAK1 [296]. Here we demonstrated that the phosphorylation of CaMKII at 
Thr286 (Fig. 19, Panels C, D) but not LKB1 (Fig. 19, Panels A, B) or TAK1 (Fig. 19, Panels E, 
F) was significantly higher in the insulin-resistant skeletal muscle of OZ rat compared to LZ rats 
(Fig. 19). Although not investigated here, it is thought that CaMKII activation is stimulated by 
elevated calcium and the increased association of CaMKII with calcium/calmodulin [297]. 
Whether the increased phosphorylation of CaMKII we observe here is responsible for the 
increased AMPK phosphorylation found in insulin resistant soleus of OZ rat will require further 
experimentation.  
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Recent studies have suggested that the phosphorylation (activation) of PKR may be 
involved in the depression of protein synthesis while also causing an increase in protein 
degradation [290, 298]. PKR is regulated by double-stranded RNA (dsRNA), which initiates 
autophosphorylation at multiple Ser and Thr residues resulting in an increase in enzyme activity. 
Here we demonstrated that the phosphorylation (activation) of PKR appears to be decreased after 
one week of overload in both LZ and OZ rats, but that the degree of PKR phosphorylation 
appears to be significantly higher in the overloaded OZ after three weeks of overload (Fig. 20). 
Why insulin-resistance might be associated with differences in the regulation of PKR is currently 
unclear.  
To examine how changes in the amount of activated PKR might influence the activation 
of molecules thought to be important in regulating protein synthesis, we next examined the 
phosphorylation of eIF2α. It has been hypothesized that PKR activation gives rise to the 
phosphorylation of eIF2α at Ser51, which in turn results in the inactivation of eIF2α and the 
inhibition of translational initiation [299]. As expected from our PKR data, the PKR dependent 
eIF2α phosphorlyation at Ser51 was significantly higher in overloaded OZ rat compared to LZ 
rat after three weeks of overload (Fig. 21). In addition to eIF2α, the glycogen synthase kinase-3β 
(GSK-3β) has also been proposed to negatively regulate cellular growth, with inhibition of this 
protein by protein phosphorylation considered an important mechanism of hypertrophy in 
cardiac tissue [300]. Similar to our data for CaMKII and PKR, we found increases in 
phosphorylation (inactivation) of GSK-3β (Ser9) following 7 days overload in both the lean and 
obese rats, but no increase in phosphorylation of GSK-3β at Ser9 in obese rats after 3 weeks of 
overload (Fig. 22). Whether this change in GSK-3β activation directly contributes to the 
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diminished hypertrophic response we observe in the insulin resistant soleus muscle is not known 
and cannot be determined from the present experimental design.  
To further explore the potential effects of PKR activation on protein degradation, we next 
examined the phosphorylation of p38 MAP kinase. It is postulated that that PKR activation can 
lead to the phosphorylation of p38 MAP kinase, which in turn, has been associated with the 
activation of the ubiquitin–proteasome pathway [33, 186]. Consistent with our PKR data, the 
phosphorylation of p38 MAP kinase (Thr180/Tyr182) was significantly higher in the overloaded 
OZ rat compared to LZ rat after three weeks of overload (Fig. 23).  To investigate the potential 
downstream effects of elevated p38 MAP kinase activation, we next measured the degree of 
protein ubiquitination. Ubiquitin is a conserved polypeptide that when covalently linked to 
cellular proteins acts to target that protein for degradation by the 26S proteosome [301]. As 
expected, we found that the level of ubiquitination was much higher in insulin-resistant skeletal 
muscle compared to normal muscle after 3 weeks overload (Fig. 24). 
Figure 25 summarizes results from the present study in concert with previous conclusions 
on the roles of AMPK, CaMKII, PKR, eIF2α, GSK-3β, and p38 MAP kinase signaling in various 
cell types.  
 
The findings support our hypothesis that the attenuation of muscle growth and mTOR 
activation following increased muscle loading observed with insulin resistance may be related to 
alterations in AMPK and PKR signaling. Considered in the context of our previous data showing 
diminished muscle hypertrophy with insulin resistance [287], the results suggest that muscle 
overload in the OZ soleus muscle is associated with alterations in AMPK, PKR, eIF2α and p38 
MAP kinase phosphorylation.  
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Figure 25: Schematic representation of possible mechanism(s) for attenuation of hypertrophy in 
obese insulin-resistant skeletal muscle  
With the exception of the latter, each of these changes would be predicted to decrease protein 
synthesis. Conversely, the increased activation of p38 MAP kinase activation, and the increase in 
protein ubiquination occurring in parallel to this finding, would be thought to lead to increases in 
the amount of protein degradation. Although our experimental design precludes the investigation 
of cause and effect, this study nonetheless provides new insight into why insulin resistance may 
be associated with differences in the ability of skeletal muscle to adapt following an overload 
stimulus.  
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SPECIFIC AIM III: To investigate whether insulin resistance affects the regulation of the 
HSPs (HSP27, HSP60, HSP70 and HSP90), MAPKs (ERK1/2 and JNK) and muscle-specific 
miRNA’s (miR-1 and miR133a) during muscle hypertrophy.  
PAPER 3 
The following paper corresponds to the specific aim III. 
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Overload induced heat shock proteins (HSPs), MAPK and miRNA (miR-1 and 
miR133a) response in insulin-resistant skeletal muscle 
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Abstract 
Heat shock proteins (HSPs), mitogen-activated protein kinases (MAPKs) and muscle-
specific miRNA have been reported to be associated with skeletal muscle adaptation to 
physiological stimuli. Little is known about regulation of these with insulin resistance. The 
purpose of this study was to determine the overload induced alterations in HSPs, MAPKs and 
miRNA in insulin-resistant muscle. To this end, we examined the regulation of HSPs (HSP27, 
HSP60, HSP70 and HSP90), MAPKs (ERK1/2 and JNK) and muscle-specific miRNAs (miR-1 
and miR133a) in 7-day and 21-day overloaded soleus muscles of OZ versus LZ rats. Overload 
regulates the expression of HSPs in a similar pattern in both LZ and OZ rat. The phosphorylation 
of HSP27 at Ser82 was increased in both LZ and OZ animals after 7 days overload, where as it 
was significantly increased only in LZ rats after 21 days overload. The basal phosphorylation 
levels of p42 MAPK were significantly higher in insulin-resistant soleus muscle compared to 
normal soleus muscle. The phosphorylation levels of p44-, p42-, P46- MAPK were significantly 
higher in both LZ and OZ rat with overload, with higher magnitudes in LZ compared to OZ. The 
miR-1 and miR133 expression levels were lower in insulin-resistant muscle, and overload 
decreased the mir-1 expression in both LZ and OZ, with much higher magnitudes in normal 
muscles. Combined, these results are the first to report alterations in the regulation of HSPs, 
MAPKs and muscle-specific miRNAs with overload in insulin-resistant skeletal muscle and 
suggest that might play a role in muscle adaptation to insulin resistance.   
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Introduction 
The adaptation of skeletal muscle to physiological and pathological stimuli is thought to 
be governed by the activation of intracellular signaling cascades. Previous data from our lab have 
suggested that insulin resistant muscle is characterized by a diminished hypertrophic response 
and that this response is associated with decrements in the activation of the mammalian target of 
rapamycin (mTOR) signaling [4, 287]. Whether other signaling systems may also play a role in 
this response is not well understood.  
It is thought that the heat shock proteins (HSPs) are important components of the cellular 
protective response and have been implicated in the chaperoning of unfolded proteins, the 
inhibition of apoptosis, and in stabilization of the cytoskeleton [187-191]. Previous studies 
demonstrated the induction of HSP proteins following high force eccentric contraction, aerobic 
exercise, and during the development of muscle hypertrophy [42, 43, 302].  However, it is not 
clear whether the regulation of these molecules is altered with insulin-resistance. 
Mitogen-activated protein kinases (MAPKs) are another class of stress responsive 
proteins that are thought to be involved in the regulation of protein synthesis and cellular 
proliferation [198-200]. The MAPK proteins are activated by dual phosphorylation prior to their 
translocation to the nucleus, where they are capable of regulating various transcriptional factors 
[202, 203]. Previous studies have demonstrated that the extracellular regulated kinase 1/2 
(ERK1/2) and c-Jun N-terminal kinase (JNK) MAPK proteins are involved in the regulation of 
skeletal muscle hypertrophy following increased loading [44-47, 214]. If or how insulin 
resistance may affect MAPK signaling in response to increased muscle loading has, to our 
knowledge, not been investigated.  
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 In addition to these signaling cascades, recent data have strongly suggested the 
involvement of muscle-specific miRNAs (miR-1, miR-133a and miR-206) in load induced 
skeletal muscle remodeling [7, 303, 304]. MicroRNAs are small endogenous ~ 22-nucleotide, 
non-coding RNAs and a newly emerging class of trans-factors, which repress gene expression by 
inhibiting the translation of target mRNAs through interacting with the 3
’
- untranslated region 
(3’UTR) [50, 51, 305]. Among the muscle-specific miRNA’s, miR-1 and miR-133a are 
important for embryonic muscle growth [52], myoblast differentiation and proliferation by 
regulating the expression of SRF, MyoD and MEF2 [53], and miR-206 plays a role in 
myogenesis [54]. A recent study by McCarthy and Esser (2007) reported decreased expression of 
miR-1 and miR-133a following 7days of functional overload and suggested this response acted 
to remove the repression of hypertrophic regulators [7]. How insulin resistance may affect the 
regulation of muscle-specific miRNAs during muscle hypertrophy is currently unclear. 
Using the same animals and tissues from  in our previous work [287], here we investigate 
whether insulin resistance affects the regulation of the HSPs (HSP27, HSP60, HSP70 and 
HSP90), MAPKs (ERK1/2 and JNK) and muscle-specific miRNA’s (miR-1 and miR133a), 
during muscle hypertrophy. Our data suggest that the alterations in the regulation of HSPs, 
MAPKs and muscle-specific miRNAs may be associated with the diminished ability of insulin 
resistant muscle to undergo hypertrophy following muscle overload. 
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Materials and Methods 
 Materials. 
Primary antibodies against HSP27 (#2442), phospho-HSP27 (Ser82) (#2401), HSP60 
(#4870), HSP70 (#4872), HSP90 (#4877), phospho-HSP90 (Thr5/7) (#3488), p44/42 MAPK 
(ERK1/2) (#9102), phospho-p44/42 MAPK (Thr202/Tyr204)(#4377), JNK/SAPK (#9252), 
phospho-JNK/SAPK (Thr183/Tyr185) (#9251), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH,#2118) and secondary antibody conjugated with horseradish peroxidase (HRP) (anti-
rabbit (#7074) were purchased from Cell Signaling Technology (Beverly, MA). The Laemmli 2 
× sample buffer was from Sigma-Aldrich (St. Louis, MO). Pierce Tissue Protein Extraction 
Reagent (T-PER), Pierce 660nm protein assay reagent (#22660), GE Healthcare Amersham 
ECL™ Western Blotting Detection Reagents (RPN2106) and Advance Western Blotting 
Detection Kit (RPN2135) were from Thermo Fisher Scientific Inc. (Rockford, IL). The PAGEr 
Gold Precast gels (10%) were from purchased from Lonza (Rockland, ME). 
Animal Care. 
 All procedures were performed in accordance with the Marshall University Institutional 
Animal Care and Use Committee (IACUC) guidelines, using the criteria outlined by the 
American Association of Laboratory Animal Care (AALAC).  The animals and tissues used in 
this study have been previously examined [287]. Young male LZ (n=12) and OZ (n=12) rats 
were obtained from the Charles River Laboratories. All animals were 12 wk of age at the 
completion
 
of this study. Rats were housed two per cage in an AAALAC approved vivarium. 
Housing conditions consisted of a 12 H: 12 H dark-light cycle and temperature was maintained 
at 22° ± 2°C. Animals were provided food and water ad libitum and allowed to recover from 
shipment for at least two weeks before experimentation. During this time the animals were 
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carefully observed and weighed weekly to ensure none exhibited signs of failure to thrive, such 
as precipitous weight loss, disinterest in the environment, or unexpected gait alterations.  
In vivo model of muscle hypertrophy. 
 Unilateral overload of the soleus muscle for 1 and 3 weeks was achieved through the 
surgical ablation of the medial and the proximal two-thirds of the lateral head of the 
gastrocnemius [109]. The unilateral ablation model allows within animal comparisons, thus 
eliminating bias due to systemic factors. Rats were anesthetized with a ketamine–xylazine (4 : 1) 
cocktail (50 mg/kg, I/P) and, the distal two-thirds of the gastrocnemius muscle were surgically 
removed from the left hindlimb as previously described [109]. A sham (control) operation was 
performed on the right hindlimb. The sham procedure consisted of an incision through the skin, 
followed by blunt isolation of the Achilles tendon and gastrocnemius muscle prior to closure. 
Animals were active immediately after recovering from anesthesia, and were checked twice daily 
during the 7 day postoperative period. No signs of infection or other complications were 
observed postoperatively.  
Tissue collection.  
Soleus muscles were collected 7 days (n = 6 LZ-7 and
 
n = 6 OZ-7) or 21 days (n = 6 LZ-
21 and n = 6 OZ-21) after
 
the synergist ablation procedure. Animals were
 
12 wk old at the time 
of tissue collection. Rats were anesthetized with a ketamine–xylazine (4: 1) cocktail (50 mg/kg, 
I/P) and supplemented as necessary for reflexive response. Soleus muscles from both legs were 
quickly removed, trimmed of excess connective tissue, weighed on an analytical balance, frozen 
in liquid nitrogen, and stored at −80◦C until further analysis.  
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Tissue protein extraction. 
Muscles were homogenized in a Pierce Tissue Protein Extraction Reagent (T-PER) (10 
mL/g tissue; Rockford, IL, USA) that contained protease inhibitors (P8340, Sigma-Aldrich, Inc., 
St. Louis, MO, USA) and phosphatase inhibitors (P5726, Sigma-Aldrich, Inc., St. Louis, MO, 
USA). After incubation on ice for 30 min, the homogenate was collected by centrifuging at 
12,000 g for 5 min at 4
◦
C. The protein concentration of homogenates was determined via the 
Bradford method (Fisher Scientific, Rockford, IL, USA). Homogenate samples were boiled in 
Laemmli 2× sample buffer (Sigma-Aldrich, Inc., St. Louis, MO, USA) for 5 min prior to SDS-
PAGE. 
SDS-PAGE and immunoblotting. 
Forty micrograms of total protein from each sample was separated on a 10% PAGEr 
Gold Precast gel (Lonza, Rockland, ME, USA) and then transferred to a nitrocellulose 
membrane. Visual verification of transfer and equal protein loading amongst lanes was 
accomplished by Ponceau S staining of the membranes. Immunodetection of antigens was 
performed as described previously [15, 68]. Briefly, membranes were blocked for 1 h at room 
temperature in blocking buffer (5% non-fat dry milk in TBS-T (20mM Tris-base, 150mM NaCl, 
0.05% Tween-20), pH 7.6), serially washed in TBS-T at room temperature, then incubated 
overnight at 4
◦
C in primary antibody buffer (5% BSA in TBS-T, pH 7.6, primary antibody 
diluted 1:1000), followed by washing in TBS-T (3X 5 min each), and incubation with HRP- 
conjugated secondary antibody (anti-rabbit (#7074) or anti-mouse (#7076), Cell Signaling 
Technology, Inc., Danvers, MA, USA) in blocking buffer for 1 h. After removal of the secondary 
antibody, membranes were washed (3X 5 min each) in TBS-T and  protein bands visualized on 
reaction with ECL reagent (Amersham ECL Western Blotting reagent RPN 2106, GE Healthcare 
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Bio-Sciences Corp., Piscataway, NJ, USA). Target protein levels were quantified by 
AlphaEaseFC image analysis software (Alpha Innotech, San Leandro, CA, USA) and normalized 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
miRNA expression analyses. 
For miRNA isolation, 25 mg pieces of soleus muscle tissue from each animal were 
pulverized with mortar and pestle in liquid nitrogen. Then miRNA was isolated from these 
pulverized tissues using miRVana miRNA Isolation Kit according to manufacturer’s directions 
(Ambion, Austin, TX). cDNA synthesis from miRNA was performed using the QuantiMir RT kit 
(System Bioscience) according to the manufacturer’s protocol. SYBR green-based real-time 
qPCR was performed by using a 7500 Real-Time PCR system (Applied Biosystems, Foster City, 
CA) and gene-specific primers for the miRNA of interest designed according to the QuantiMir 
RT kit’s guidelines and synthesized by Integrated DNA Technologies (IDT, Coralville, IA).  
Melt analysis was used after each PCR run to ensure amplification of only a single product. To 
account for possible differences in the amount of starting miRNA, all samples were normalized 
to miR-206 as the expression of this molecule was not different between animal models or 
following overload. Relative fold changes in miRNA were determined from the Ct values after 
normalization to housekeeping gene using the 2
-∆ct
 method (modified Levak method) [306]. 
Statistical analysis.  
Results are presented as mean + SE. Data were analyzed using the Sigma Stat 3.5 
statistical program. Data were analyzed using two way analysis of variance (ANOVA) followed 
by the Student–Newman–Keuls post hoc testing where appropriate. Values of P < 0.05 were 
considered to be statistically significant.  
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Results 
The impaired hypertrophic response of insulin resistant muscle is associated with diminished 
HSP27 phosphorylation.  
As outlined previously, the OZ rat exhibited a significantly higher body weight than the 
LZ at both 7 and 14 days of observation (464 ± 12 gm vs. 302 ± 3 gm at 7 days; P < 0.05; 
460±26 vs. 289±10 mg at 21 days; P < 0.05) while soleus muscle wet weights were significantly 
lower in the OZ compared to the LZ (128 ± 11 mg vs. 150±6 mg; at 7 days; P < 0.05; 128.0±6.5 
vs. 141.0±8.3 mg at 21 days; P < 0.05) [287]. To examine the effect of insulin resistance on the 
regulation of HSP molecules with overload, we compared the expression and phosphorylation 
levels of HSP27, HSP60, HSP70 and HSP90. Muscle loading did not alter the expression of 
HSP60, HSP70 and HSP90 in either the LZ or OZ animals (Fig. 27 and 28A). The expression of 
the small heat shock protein HSP27 was increased in both LZ and OZ animals after 7 and 21 
days of overload (P < 0.05; Fig. 26A). The phosphorylation of HSP27 at Ser 82 was increased in 
both LZ and OZ animals after 7 days of increased loading, while it was significantly increased 
only in the LZ rats after 21 days of overload (P < 0.05; Fig. 26B). 
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Figure 26: Immunoblot analysis of the small heat shock protein, HSP27 (A) protein content and 
(B) phosphorylation at Ser82, in control and loaded soleus muscles of LZ and OZ. All the protein 
quantifications were done after normalization by abundance of GAPDH protein; n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
 
 
 
Figure 27: Immunoblot analysis of the expression levels of heat shock proteins,(A) HSP60 and 
(B) HSP70 in control and overloaded soleus muscles of LZ and OZ. All the protein 
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quantifications were done after normalization by abundance of GAPDH protein; n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
 
 
 
Figure 28: Immunoblot analysis of the heat shock protein, HSP90(A) protein content and (B) 
phosphorylation at Thr5/7, in control and loaded soleus muscles of LZ and OZ. All the protein 
quantifications were done after normalization by abundance of GAPDH protein; n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
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Insulin resistance alters the overload-induced phosphorylation of MAPK proteins in slow twitch 
soleus muscle.  
To examine the effect of insulin resistance on the activation of MAPK proteins with 
overload, we compared the protein content and phosphorylation of p44/42 MAPK (ERK1/2) and 
JNK / SAPK between control and overloaded muscles. The amount of ERK1/2 was unaltered 
with muscle overload in both LZ and OZ animals, where as the phosphorylation levels of p44 
and p42 MAPK at Thr202 / Tyr204 was significantly higher in overloaded LZ and OZ muscles at  
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Figure 29: Immunoblot analysis of the p44/42(ERK1/2) (A) protein content and (B) 
phosphorylation at Thr202/Tyr204, in control and loaded soleus muscles of LZ and OZ. All the 
protein quantifications were done after normalization by abundance of GAPDH protein; n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
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Figure 30: Immunoblot analysis of the SAPK/JNK (A) protein content and (B) phosphorylation 
at Thr183/Tyr185, in control and loaded soleus muscles of LZ and OZ. All the protein 
quantifications were done after normalization by abundance of GAPDH protein; n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05. Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
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both 7 and 21 days (P < 0.05; Fig. 29). The magnitude of ERK1/2 phosphorylation was higher in 
LZ compared to OZ rats. The basal phosphorylation levels of p42 MAPK were significantly 
higher in insulin resistant soleus muscle compared to normal soleus muscle (P < 0.05; Fig. 29). 
Muscle loading did not alter the expression of JNK/SAPK in either the LZ or OZ solei muscles 
(Fig. 30). The phosphorylation level of p46 (JNK1) at Thr183/Tyr185 was significantly higher in 
both LZ and OZ rat with overload at both 7 and 21 days, while the degree of phosphorylation 
was higher in the LZ compared to OZ soleus (P < 0.05; Fig. 29).  
Muscle specific miRNA expression following muscle overload is influenced by insulin resistance.  
The amount of mir-1 and miR133 in insulin resistant soleus muscles was less than that 
observed in the normal soleus muscle (P < 0.05; Fig. 31 and 32). Both 7 days and 21 days 
overload decreased mir-1 levels in both LZ and OZ, but the magnitude of decrease was higher in 
normal muscle compared to insulin-resistant muscle (P < 0.05; Fig. 31). The expression levels of 
miR-133a decreased significantly in the LZ animals with overload at both 7 and 21 days (P < 
0.05; Fig. 32). In contrast, miR-133a levels in the OZ rat were increased significantly with 
overload at both 7 and 21 days (P < 0.05; Fig. 32). 
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Figure 31: Insulin resistance alters the regulation of miR-1 with overload. Quantitative RT-PCR 
analyses of miR-1 expression in control and loaded soleus muscles of LZ and OZ rats using 
SYBR green I. miR-1 expression was normalized to miR-206 expression, which was found to be 
not change with either animal model or with functional overload. n = 6. †Significantly different 
from contralateral control muscle, * Significantly different from lean control value, P < 0.05. 
Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean Zucker; OZ, obese 
Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese overload. 
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Figure 32: Insulin resistance alters the regulation of miR-133a with overload. Quantitative RT-
PCR analyses of miR-133a expression in control and loaded soleus muscles of LZ and OZ rats 
using SYBR green I. miR-133a expression was normalized to miR-206 expression, which was 
found to be not change with either animal model or with functional overload. n = 6. 
†Significantly different from contralateral control muscle, * Significantly different from lean 
control value, P < 0.05.  Abbreviations: 7d, 7 days of loading; 21d, 21 days of loading; LZ, lean 
Zucker; OZ, obese Zucker; LC, lean control; LO, lean overload; OC, obese control; OO, obese 
overload. 
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Discussion 
Skeletal muscle adaptation to increased load is characterized by increases in muscle mass 
(hypertrophy) that is thought to be regulated by the activation of several signaling cascades. 
Previously we demonstrated that the degree of muscle hypertrophy following an overload 
stimulus was decreased in the insulin-resistant obese Zucker (fa/fa) rat (OZ) when compared to 
that observed in the LZ rat, and that this attenuation was associated with multiple-level 
decrements in mammalian target of rapamycin (mTOR) and its downstream translational 
signaling intermediates, p70S6k , rpS6  and eukaryotic initiation factor 4E-binding protein 1 (4E-
BP1) [287]. Here we extend upon those findings and demonstrate that overload in the OZ rat 
soleus is associated with diminished HSP27 phosphorylation, decreased MAPK phosphorylation 
and alterations in the regulation of muscle specific miRNAs.  
Insulin resistance is associated with alterations in HSP27 phosphorylation following muscle 
overload.  
Previous reports have demonstrated that Hsp27 expression increases in response to 
increased muscle load in both human and animal muscles [43, 307, 308]. Consistent with these 
data, here we show that Hsp27 expression was increased with overload in both the LZ and OZ 
soleus muscles. Overload also led to a significant increase in the phosphorylation or activation of 
Hsp27 at Ser82 in normal muscle; however, this response appeared to be attenuated in the 
insulin-resistant soleus. In vitro studies have suggested that the increased phosphorylation of 
Hsp27 is involved in maintaining cytoskeletal protein integrity. Whether HSP27 exhibits a 
similar function in vivo is currently unclear and beyond the scope of the present study. 
Additionally, it is also unknown why insulin resistance was associated with diminished overload-
induced activation (phosphorylation) of Hsp27. Nonetheless, given that Hsp27 is a substrate for 
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the MAPK proteins [214, 309, 310], it is possible that the decreased activation of MAPK with 
overload seen in the OZ soleus (Figures 29 & 30) may be related. Future experiments designed 
to directly test this possibility will no doubt be useful in establishing cause and effect. 
Insulin resistance is associated with decreases in overload-induced MAPK phosphorylation.  
Several lines of evidence suggest that MAPKs play an integral role in the adaptation of 
skeletal muscle to alterations in contractile loading [214, 311-314]. It is thought that the 
phosphorylation (activation) of MAPK proteins is important in regulating such diverse processes 
as gene expression, glucose uptake, cell replication, and protein synthesis [315, 316]. The basal 
phosphorylation levels of p42- MAPK in the insulin-resistant soleus muscle was significantly 
higher compared to that observed in the normal soleus. Overload was found to increase the 
activation of p44- and p42-MAPK in both normal and insulin resistant soleus, however the 
magnitude of activation was higher in normal compared to that observed in insulin resistant 
soleus. Given the possibility that ERK1/2 activation is associated with skeletal muscle 
hypertrophy [317, 318], the differences in magnitude of activation of ERK1/2 between lean and 
obese rats with overload may help to explain the decreased hypertrophic response seen in the OZ 
animals.  Although the exact mechanism for ERK1/2 involvement in muscle hypertrophy has yet 
to be elucidated, it has been hypothesized that ERK1/2 activation is associated with elevations in 
translational initiation, which may occur  through increased phosphorylation of the eukaryotic 
initiation factor eIF4E [319]. 
Muscle-specific miRNAs and insulin-resistance 
It has been suggested that muscle-specific miRNAs may play a key role in the adaptation 
of skeletal muscle. For example, the expressions of mir-1and  miR133 are decreased in response 
to functional overload [7], chronic endurance training [304], and resistance exercise [320]. Here 
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we investigated whether insulin-resistance affects the expression and regulation of muscle-
specific miRNAs with overload. Our semi-quantitative PCR data demonstrated that insulin 
resistance was associated with a lower expression of mir-1 and mir-133 compared to that 
observed in the non-diabetic soleus. The physiological significance and mechanism(s) for loss of 
muscle-specific miRNAs with insulin resistance are currently unclear. However, recent data 
suggest that the expression of mir-1 and mir-133, at least in C2C12 cells, may be regulated by 
the myogenic regulatory factors (MRFs) myogenin and MyoD [321]. Whether a similar finding 
exists in vivo is currently unclear. Previous work from our laboratory failed to demonstrate 
differences in the regulation of MRFs with overload in OZ rat [287]. These findings are 
consistent with the possibility that these MRFs may play a diminished role in regulating the 
expression of mir-1 and mir-133 in LZ and OZ animals. Similarly, like that observed for most of 
the known miRNA species, the exact role that these molecules may play in vivo has yet to be 
fully elucidated.  
In addition to the possibility that insulin resistance may affect miRNA expression 
profiles, we also observed that muscle overload is associated with diminished mir-1 expression 
in both the LZ and OZ rats (Figure 31). These results are in agreement with recent findings by 
McCarthy and Esser, who reported a 50% decrease in expression of mir-1 after 7-days functional 
overload in the mouse plantaris muscle [7]. Interestingly, the overload associated decreases 
observed in the present study appeared to be higher in the LZ compared to OZ after 7- and 21-
days of overload (Figure 31). Similar results to what we had observed with mir-1 were seen 
when we examined mir-133a expression in the LZ animals (Figure 32). Conversely, in the OZ 
animals overload appeared to increase the expression of this molecule (Figure 32). Whether these 
findings are directly related to the diminished overload-induced hypertrophy we see in the OZ rat 
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soleus is currently unclear and beyond the scope of the present study. Similarly, why insulin-
resistance might be associated with differences in how overload regulates miRNA expression is 
not known. 
Summary and conclusions 
The findings of the present study suggest that the impaired hypertrophic response seen in 
insulin resistant muscle appears to be associated with alterations in HSP and MAPK 
phosphorylation along with changes in the way muscle overload regulates muscle specific 
miRNA expression. These data extend our previous work showing that insulin resistance is 
characterized by differences in the overload induced activation of mTOR signaling pathways.  
Future studies perhaps using pharmacological and genetic manipulation will be useful in 
assessing the cause and effect of our findings and may offer therapeutic insight for the 
maximization of muscle growth in diabetic individuals.  
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CHAPTER IV 
GENERAL DISCUSSION 
The primary purpose of this study was to investigate why insulin resistance may be 
associated with a diminished ability of skeletal muscle to adapt to an overload stimulus. To 
address this purpose, we examined the regulation of mTOR signaling, AMPK signaling, PKR 
signaling, HSPs (HSP27, HSP60, HSP70 and HSP90), MAPKs (ERK1/2 and JNK) and muscle-
specific miRNA’s (miR-1 and miR133a), during the initial and latter phases of muscle 
hypertrophy in insulin resistant soleus muscles of the OZ rat. 
Diabetes is considered a global health problem that afflicts 171 million people worldwide 
(International Diabetes Federation, 2007). This epidemic is associated with increased mortality 
and morbidity which negatively affects quality of life [64]. The OZ  rat presents abnormalities 
similar to those seen in human metabolic syndrome and is a widely used model of insulin 
resistance [56]. Skeletal muscle insulin resistance is the key defect in maintaining glucose 
homeostasis and is thought to play a central role in the pathogenesis of metabolic syndrome [9, 
10]. Skeletal muscle is a primary consumer of blood glucose and is thought to participate in the 
control of blood glucose levels, where as other studies have demonstrated that increases in 
muscle mass or muscle hypertrophy are associated with improvements in glycemic control [284-
286]. Previous data from our laboratory has suggested that the capacity of the OZ soleus muscle 
to undergo hypertrophy in response to increased loading is diminished compared to that observed 
in the lean Zucker rat (LZ) [4].  The exact molecular mechanism(s) for these alterations in 
skeletal muscle adaption with different hypertrophic stimuli are not known. 
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Regulation of mTOR signaling with insulin resistance during muscle hypertrophy 
It is well accepted that the regulation of muscle growth is dependent upon the balance 
between protein synthesis and degradation with increases in muscle mass occurring when protein 
accretion is favored over its breakdown. One critical signaling pathway that has been shown to 
play a role in controlling protein synthesis following increased muscle loading is the mammalian 
target of rapamycin (mTOR) [22, 23]. The regulation of mTOR signaling is complex and is 
likely influenced by several upstream molecules and pathways as previous data has suggested the 
participation of phosphoinositide 3-kinase (PI3K), phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), protein kinase B/ Akt, TSC2 / Tuberin, and raptor  [22, 147, 148, 261-
263]. The mTOR functions to regulate several physiological processes including gene 
transcription, protein
 
metabolism, cell cycle control, and cytoskeleton organization [24, 25]. 
When active (phosphorylated), mTOR is thought to promote protein translation by controlling 
the activity of several downstream effectors, including the 70 kDa ribosomal protein S6 kinase 
(p70S6k), ribosomal protein S6 (rpS6), eIF4E-binding protein 1 (4E-BP1), and eukaryotic 
elongation factor 2 (eEF2) [27, 264]. 
In the present study we demonstrated that the phosphorylation (activation) of mTOR with 
insulin resistance appears to be similar after one week of overload before becoming significantly 
decreased by three weeks of overload. This latter finding is consistent with our data 
demonstrating that the insulin resistant soleus exhibits a reduced ability to undergo hypertrophy 
following eight weeks of mechanical overload [4]. To examine how this defect in mTOR 
signaling might affect the regulation of molecules thought to be involved in controlling protein 
translation , we next examined how insulin resistance affected the phosphorylation of eukaryotic 
initiation factor (eIF) 4E
 
binding protein-1 (4E-BP1) and p70S6k in response to increased muscle 
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loading. As expected from our mTOR data, the phosphorylation of the mTOR substrates, 4E-
BP1 and p70S6k were significantly less in the OZ rat compared to that observed in the LZ rat.  
To confirm these data, we also examined the regulation of the p70S6k substrate, 
ribosomal protein S6 (rpS6) [270]. Consistent with our findings for p70S6k, we found that the 
degree of rpS6 phosphorylation at Ser 235/236 following three weeks of overload was 
diminished in the OZ compared to their lean counterparts. Further, we demonstrated the ability 
of the soleus to activate (phosphorylation at both Ser473 and Thr308) Akt in the OZ appears to 
be diminished compared to that observed in the LZ rat. How this might affect the activation of 
other signaling molecules is currently unclear; however, it is likely that Akt can influence the 
activity of mTOR through its ability to phosphorylate the product of the tuberous sclerosis
 
complex TSC2 gene, also termed tuberin. The phosphorylation of tuberin (Thr1462) is 
diminished in the lean Zucker rat although it is unaltered in OZ rat following three weeks of 
overload. Because decreased tuberin phosphorylation should lead to a decrease in mTOR 
activity, it is likely that the differences in mTOR phosphorylation we see between models is not 
due to alterations in TSC2 regulation. In an effort to explore other possible mechanisms for the 
attenuated hypertrophy we observe in the OZ animals, we next examined if muscle overload was 
associated with alterations in the amount of myogenic regulatory factors, MyoD and myogenin, 
which have been posited to be involved in regulating satellite cell activation. Consistent with 
previous work examining the myogenin and myoD levels in rat soleus muscle after 4 weeks of 
surgical overload [281], we observed no changes in the amount of myogenin and myoD with 
overload in either the LZ and OZ animals. Taken together, these data suggest that insulin 
resistance may be associated with a decrease in the ability of the soleus muscle to undergo 
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muscle hypertrophy and that this finding may be related to differences in mTOR, p70S6k, Akt, 
and rpS6 signaling. 
Regulation of AMPK and PKR -dependent signaling with insulin resistance during muscle 
hypertrophy 
AMP-activated protein kinase (AMPK) is a serine/threonine kinase and master regulator 
of cellular energy metabolism that is thought to act as a negative regulator of protein synthesis 
[26, 34]. It has been shown that AMPK may inhibit protein synthesis through its ability to 
suppress mTOR activation [22, 34, 135, 288, 289]. The factors controlling the activity of AMPK 
have not been fully elucidated; however, it is thought that protein tumor suppressor LKB1 kinase 
[35, 169, 170], calcium/calmodulin-activated protein kinase (CaMKII) [36, 171], and 
transforming growth factor-β-activated kinase-1 (TAK1), a member of the mitogen-activated 
protein (MAP) kinase family, may be involved  [37, 172]. 
In the present study, we found that the phosphorylation of Thr172 appears to be similar 
after one week of overload in the LZ and OZ animals, but that it is significantly higher in the 
overloaded OZ rat compared to LZ rat after three weeks of overload. These latter data are 
consistent with our previous report demonstrating a decrease in the ability of the OZ to undergo 
muscle hypertrophy following overload [4]. In addition, because AMPK is thought to inhibit the 
activity of mTOR [34, 135], the increased AMPK phosphorylation (activation) observed in the 
OZ animals may help to explain why mTOR signaling may be decreased in the OZ soleus 
following muscle overload. We have also found that the phosphorylation of CaMKII at Thr286 
but not LKB1 or TAK1, was significantly higher in the insulin-resistant skeletal muscle of OZ 
rat compared to LZ rats. Whether the increased phosphorylation of CaMKII we observe here is 
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responsible for the increased AMPK phosphorylation found in insulin resistant soleus of OZ rat 
will require further experimentation. 
Recent studies have suggested that the phosphorylation (activation) of PKR may be 
involved in the depression of protein synthesis while also causing an increase in protein 
degradation [290, 298]. Here we demonstrated that the phosphorylation (activation) of PKR 
appears to be decreased after one week of overload in both LZ and OZ rats but that the degree of 
PKR phosphorylation appears to be significantly higher in the overloaded OZ after three weeks 
of overload. To examine how changes in the amount of activated PKR might influence the 
activation of molecules thought to be important in regulating protein synthesis, we next 
examined the phosphorylation of eIF2α. As expected from our PKR data, the PKR dependent 
eIF2α phosphorlyation at Ser51 was significantly higher in overloaded OZ rat compared to LZ 
rat after three weeks of overload. To further explore the potential effects of PKR activation on 
protein degradation, we next examined the phosphorylation of p38 MAP kinase. Consistent with 
our PKR data, the phosphorylation of p38 MAP kinase (Thr180/Tyr182) was significantly higher 
in the overloaded OZ rat compared to LZ rat after three weeks of overload. To investigate the 
potential downstream effects of elevated p38 MAP kinase activation, we next measured the 
degree of protein ubiquitination. As expected, we found that the level of ubiquitination was much 
higher in insulin-resistant skeletal muscle compared to normal muscle after 3 weeks overload. 
Taken together, these results suggest that insulin resistance attenuates overload-induced skeletal 
muscle hypertrophy through the activation of AMPK and PKR, leading to inhibition of mTOR 
signaling and phosphorylation of eIF2α and depression of protein synthesis, together with PKR 
mediated p38 MAP kinase activation and increased protein degradation. 
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Regulation of HSPs and MAPKs with insulin resistance during muscle hypertrophy 
It is thought that the heat shock proteins (HSPS) are important components of the cellular 
protective response and have been implicated in the chaperoning of unfolded proteins, the 
inhibition of apoptosis, and the stabilization of the cytoskeleton [187-191]. Previous studies 
demonstrated the induction of HSP proteins following high force eccentric contraction, aerobic 
exercise, and during the development of muscle hypertrophy [42, 43, 302]; however, it is not 
clear whether the regulation of these molecules is altered with insulin resistance. Here, we 
demonstrated that overload led to a significant increase in the phosphorylation or activation of 
Hsp27 at Ser82 in normal muscle; however, this response appeared to be attenuated in the insulin 
resistant soleus. 
Mitogen-activated protein kinases (MAPKs) are another class of stress responsive 
proteins that are thought to be involved in the regulation of protein synthesis and cellular 
proliferation [198-200]. Previous studies have demonstrated that the extracellular regulated 
kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) MAPK proteins are involved in the 
regulation of skeletal muscle hypertrophy following increased loading [44-47, 214]. If or how 
insulin resistance may affect MAPK signaling in response to increased muscle loading has, to 
our knowledge, not been investigated. In the present study we demonstrated that overload was 
found to increase the activation of p44- and p42-MAPK in both normal and insulin resistant 
soleus, however the magnitude of activation was higher in normal compared to that observed in 
insulin resistant soleus. Given the possibility that ERK1/2 activation is associated with skeletal 
muscle hypertrophy [317, 318], the differences in magnitude of activation of ERK1/2 between 
lean and obese rats with overload may help to explain the decreased hypertrophic response seen 
in the OZ animals. Taken together, these results suggest that the impaired hypertrophic response 
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seen in insulin resistant muscle appears to be associated with alterations in HSP and MAPK 
phosphorylation. 
Regulation of muscle-specific miRNAs with insulin resistance during muscle hypertrophy 
MicroRNAs (miRNAs) are small ~ 22-nucleotide, non-coding RNAs that are a newly 
emerging class of trans-factors that repress gene expression post-transcriptionally by inhibiting 
translation of target mRNAs through interaction with the 3
’
- untranslated region (3’UTR) of 
target mRNAs [50, 51, 215]. Previous studies have strongly suggested a role for muscle-specific 
miRNAs (miR-1, miR-133a and miR-206) in load induced skeletal muscle remodeling [7, 303, 
304]. Among the muscle-specific miRNA’s, miR-1 and miR-133a are important for embryonic 
muscle growth [52], myoblast differentiation and proliferation by regulating the expression of 
SRF, MyoD and MEF2 [53],and miR-206 plays a role in myogenesis [54]. How insulin 
resistance may affect the regulation of muscle-specific miRNAs during muscle hypertrophy is 
currently unclear. 
In the present study we observed that muscle overload is associated with diminished mir-
1 expression in both the LZ and OZ rats. These results are in agreement with recent findings by 
McCarthy and Esser, who reported a 50% decrease in expression of mir-1 after 7-days of 
functional overload in the mouse plantaris muscle [7]. Interestingly, the overload associated 
decreases observed in the present study appeared to be higher in the LZ compared to OZ after 7- 
and 21-days of overload. Similar results to what we had observed with mir-1 were seen when we 
examined mir-133a expression in the LZ animals. Conversely, in the OZ animals overload 
appeared to increase the expression of this molecule. Whether these findings are directly related 
to the diminished overload-induced hypertrophy we see in the OZ rat soleus is currently unclear. 
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Similarly, why insulin-resistance might be associated with differences in how overload regulates 
miRNA expression is not known. 
CONCLUSIONS 
1. The OZ rat was hyperglycemic and hyperinsulinemic compare to the LZ rat. 
2. The degree of hypertrophy following three weeks of compensatory overload was 
attenuated in insulin resistant OZ rat compared to its lean counterpart. 
3. Impaired overload-induced hypertrophy in insulin resistant skeletal muscle may be 
related to decreases in the ability of the muscle to activate mTOR and its downstream 
effectors. 
4. Impaired overload-induced hypertrophy in insulin resistant skeletal muscle was 
associated with hyperphosphorylation of AMPK and dsRNA-dependent protein kinase, 
which leads to the inhibition of mTOR signaling and phosphorylation of eIF2α and 
depression of protein synthesis, together with PKR mediated p38 MAP kinase activation 
and increased protein degradation. 
5. Skeletal muscle adaptation to increased load in the OZ rat is associated with diminished 
HSP27 phosphorylation and decreased MAPK phosphorylation. 
6. Insulin resistance alters the regulation of muscle-specific miRNAs during muscle 
hypertrophy. 
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Molecule  7d  LZ 7d  OZ 21d  LZ 21d  LZ 
p-mTOR  (S2448)     
p-p70S6k (T389)     
p-p70S6k (T421/S424)     
p-rpS6 (S235/236)     
p-eEF2 (T56)     
p 4E-BP1 (T37/46)     
p-Akt (T308)     
p-Akt (S473)     
p-PTEN (S380/T382/383)     
p-TSC2 (T1462)     
Raptor     
myo-D     
myogenin     
p-AMPKα (T172)     
p-PKR (T446)     
p-eIF2α (S51)     
p-p38 MAPK (T180/T182)     
Ubiquitin     
p-GSK-3β (Ser9)     
p-HSP27 (S82)     
HSP60     
HSP70     
HSP90     
 
Table 1 Summary of results. Alterations in expression or phosphorylation of signaling proteins in 
skeletal muscle adaptation with overload. (    = Increased,    = decreased and, 
         = unchanged compared to respective control). 
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FUTURE DIRECTIONS 
 
The present study focused on understanding the different molecular mechanisms in which 
insulin resistance may alter skeletal muscle remodeling with hypertrophy and thus may lead to 
treatment options aimed at improving skeletal muscle function. This dissertation has provided 
evidence that overload-induced skeletal muscle remodelling in the insulin-resistant OZ rat is 
associated with multiple level decrements in mTOR signaling, hyperphosphorylation of AMPK 
and PKR and altered regulation of muscle-specific miRNAs. Unfortunately, these experiments 
do not demonstrate the direct cause and effect relationship between insulin resistance and 
alterations in signaling events. As such, complementary experiments designed to directly inhibit 
or activate these signaling molecules will further enhance our understanding of mechanisms of 
skeletal muscle remodeling. For example, using genetic models of AMPK deficiency/ functional 
titration and looking at the regulation of mTOR signaling may improve our understanding of 
interaction between these two signaling pathways.  
Recent studies demonstrated the interaction of myostatin signaling with Akt/mTOR 
signaling [322, 323]. Overexpression of myostatin was associated with decreased 
phosphorylation of Akt as well as reduced phosphorylation of other components of Akt/mTOR 
signaling such as ribosomal protein S6, p70S6K and 4E-BP1 [323, 324], and blocking myostatin 
activity increased protein synthesis and ribosomal protein S6 and p70S6K phosphorylation [322]. 
Whether insulin resistance alters the regulation of myostatin signaling during muscle 
hypertrophy is not known and is worthy of investigation.   
The findings from this study demonstrated that IR is associated with altered skeletal 
muscle remodeling with contractile stimuli. However, besides IR, other co-morbidities (i.e. 
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obesity, leptin resistance) may also affect the muscle adaptation. To determine whether obesity 
affects the skeletal muscle adaptation during muscle hypertrophy, this study design should be 
repeated using a non obese insulin resistance model replacing the obese insulin resistance model. 
In addition, future studies are required to understand the leptin-mediated effect on the muscle 
remodeling. 
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